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Abstract
Obesity is associated with the development of various metabolic diseases. 
Adipose tissue-derived factors may underlie this relationship. Two novel 
adipose signals associated with increased risk of coronary heart disease were 
investigated; interleukin-6 (IL-6) and the endogenous nitric oxide inhibitor, 
asymmetric dimethyl arginine (ADMA).
The effect of the cyclo-oxygenase (COX) pathway on basal adipose IL-6 
production was examined. Basal COX-2 expression was detected in adipose 
tissue explants. There was a dose-dependent decrease in adipose IL-6 release 
by a non-selective COX inhibitor, aspirin. Cyclic AMP, and not Ca2+, was the 
intracellular mediator of IL-6 release. PGE2 EP2 and 4 signalling is mediated 
by elevation in intracellular cAMP and agonists for these receptors elevated IL- 
6. Thus, basal IL-6 secretion occurs through increased COX-2 mediated PGE2 
release signalling via EP4 receptors and elevated intracellular cAMP.
The role of the COX pathway was also investigated in adipogenesis. Aspirin 
and SC-560, a selective COX-1 inhibitor, inhibited adipocyte differentiation 
mainly by down-regulating adipogenic transcription factors. However, NS-398, 
a COX-2 selective inhibitor, was found to have no such effect. Thus, 
adipogenesis was found to be regulated by a COX-1 mediated mechanism. 
ADMA, an endogenous NO inhibitor, is cleared mainly by catabolism by 
DDAH. Significant amounts of DDAH 1 and 2 mRNA and protein were 
expressed in mouse and human adipose tissue and adipocytes. In human 
subjects, the abdominal sub-cutaneous adipose tissue released ADMA in vivo 
and circulating levels in morbid obesity were elevated. Furthermore, weight 
loss increased adipose DDAH expression and decreased systemic ADMA
2
levels. In vitro studies also showed a direct correlation between the amount of 
adipose tissue and its release of ADMA. Thus, genetic, dietary and 
pharmacological disruption of DDAH altered adipose ADMA release.
In conclusion, this work showed that two important enzymes, COX and 
DDAH, in adipose tissue have the capacity to modulate cardiovascular risk in 
obesity by their regulation of IL-6 synthesis, adipogenesis and the release of 
ADMA.
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW
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1.1 Obesity
1.1.1 Epidemiology of obesity
Obesity is not a new phenomenon. It dates back to the Stone Age, this being 
detected through archaeological evidence. However, it has never been as 
common as it is today and across such a large proportion of the world. 
Currently, the prevalence of obesity is increasing globally (WHO, 1997). Over 
the past two years, a number of reports have repeatedly underlined the 
gravity of an impending worldwide public health crisis if current trends in 
weight gain and obesity are not tackled. Worldwide, one in 10 children and 
more than 1 billion adults are overweight and at least 300 million adults are 
clinically obese (Kimm et al, 2002). One prediction is that two thirds of 
European citizens will be overweight by the year 2030. Experts predict that 
the health consequences of this could be disastrous.
Obesity is a critical public health problem that causes millions of people to 
suffer unnecessary health problems and die prematurely. This is a condition 
that contributes to approximately 400,000 deaths each year, drains the 
economy of billions of pounds annually through direct and indirect medical 
expenses, disability and lost productivity (Allison et al, 1999; Katzmarzyk et al, 
2004). The problem does not only affect developed countries. There is now a 
significant increase in overweight and obesity throughout the developing 
world. It affects all age ranges and both genders in many countries. It is 
estimated that more people will die from complications of overnutrition than of 
starvation (Rossner, 2001).
Obesity is defined in most instances by Body Mass Index (BMI), a 
mathematical calculation, derived from the weight in kilograms divided by the
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square of the height in metres (kg/m2). Body mass index is the most 
widespread tool for measuring overweight in population and clinical settings. 
By WHO criteria a BMI of less than 25 is considered normal weight, that 
between 25 to 29.9 is overweight, 30 or greater is considered obese (WHO, 
1997). While these definitions provide common benchmarks for assessment 
the risks of disease in all populations increase progressively from even lower 
BMI levels.
According to a report by the National Audit Office (NAO) 65% of English 
adults were estimated to be overweight and 19% obese (NAO, 2001). The 
report also shows approximately two-thirds of men and over half of women in 
Britain are overweight and obese. In the United States 60% of people (about 
170 million) are overweight, and 27% of people (about 70 million) are obese 
and at medical risk (Hedley et al, 2004). However, this prevalence has 
increased by about 10 -40% in many countries in the past 10 years. The most 
dramatic increase amongst European countries has been in the UK, where it 
has more than tripled since 1980.
1.1.2 Consequences of obesity
Obesity has significant co-morbidities and these are associated with 
substantial health care and social cost. The cost of obesity in Britain was 2.5 
billion pounds per year with 30,000 premature deaths in England alone in 
1998 (NAO, 2001).
Obesity is a risk factor for type 2 diabetes (Colditz et al, 1995; Chan et al,
1994), cardiovascular disease (Meigs et al, 1997), hypertension (Rocchini, 
2004), dyslipidaemia (Despres et al, 2004), sleep apnoea (Strohl et al, 2004),
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musculoskeletal disorders (Manson, 2004), degenerative disease (Felson et 
al, 1988) and some cancers (Manson et al, 1995).
Elevations in body mass increases cardiovascular disease due to elevating 
blood pressure, cholesterol, triglycerides, and increasing insulin resistance. A 
20% reduction in body weight can reduce cardiovascular risk by 40% (Savage 
et al, 2003). Furthermore this reduced risk can be maintained by keeping BMI 
within the normal range.
The prevalence of type 2 diabetes is rising dramatically throughout the world 
and it has been predicted that the number of adults with diabetes will increase 
by 46% from 151 million in 2000 to 221 million in 2010 (Amos et al, 1997). 
The incidence of diabetes increases with increasing body weight. Diabetes is 
three times more likely in obese individuals with a BMI of 28 or greater. 
Furthermore, developing type 2 diabetes is approximately 40 times more in 
adults with BMI >35 compared with their peers with a BMI between 18.5 and
24.9 (Colditz et al, 1995).
The risk of certain cancers also increases with increasing BMI (Manson et al,
1995). Other diseases associated with obesity include sleep apnoea,
i
abdominal hernias, varicose veins, gout, gall bladder disease, respiratory 
problems and liver malfunction (Bray, 2004).
Morbid obesity, indicated by a BMI over 40, is so closely associated with 
various health problems that it is regarded as a disease in its own right 
(Laville, 1993). Current trends in our society recognize morbid obesity as 
becoming an epidemic and leading to a major crisis in the near future. In the 
United States, 25% of children under the age of 16 are also approaching 
morbid obesity (Magarey et al, 2003).
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The personal economic and social costs of obesity are also significant in 
terms of reduced quality of life and poor social integration. However, this 
condition is preventable and treatable in many cases. Therefore, the first aim 
should be prevention, but it will also be important to develop strategies to treat 
those already affected with obesity, as even modest weight loss of 5 -10% 
has been shown to reverse many of the co-morbidities associated with obesity 
and to result in significant health gains (Bray, 2004).
1.1.3 Causes of obesity
Obesity is a complex, multifactorial, chronic disease that is caused by a 
combination of both genetic and environmental influences (Speakman, 2004). 
While obesity has been shown to be due to single gene mutations, such as 
seen in humans with leptin or leptin receptor gene mutations, these are rare 
and only constitute a minority of normal obesity (Zhang et al, 1994). 
Furthermore, despite the identification of over 360 genes that are implicated in 
obesity, genetic abnormalities on their own cannot explain the rapid increases 
in obesity reported globally today (Rossner et al, 2002).
Evidence suggests that environmental factors may be more attributable to the 
current epidemic of obesity (Speakman, 2004). The consequence of 
increasing food intake and decreasing physical activity results in the 
accumulation of excess body fat and obesity. Since the 2nd World War 
western societies have become progressively more affluent. Both men and 
women are also participating in the work environment and income generation. 
While this increases personal wealth, it also contributes to lack of free time. 
Simultaneously, technological advances. have resulted in more sedentary 
lifestyles, at the workplace, at home and in leisure pursuits. The increased
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spending power and reduction in free time of the population has given rise to 
the fast food industry.
Increasing energy intake especially with cafeteria diets, snacking and highly 
palatable foods that use excess dietary fat often leads to weight gain (Prentice 
et al, 1995). Higher energy content per gram is provided by fat than protein 
and carbohydrate. Fat produces fewer satiety signals and is less able to 
suppress hunger and importantly it has a higher capacity for storage in the 
body (Blundell, 1993).
Decreasing energy expenditure, especially with modern sedentary lifestyles, 
appears to be at least as important as high caloric diets in the development of 
obesity. Modern technologies especially in the past three decades have 
affected energy usage. Increasing inactivity such as using cars, using lifts, 
number of hours watching television and working with computers, use of 
remote controls and mobile telephones and other aspects of technology save 
on a great deal of energy expenditure over the time (Prentice et al, 1995; 
Armstrong et al, 1998).
Obesity will develop if individuals fail to match their energy intake to their 
energy needs. Therefore, according to ‘energy balance equation theory’ any 
increase in energy intake (food) or decrease in energy expenditure (basal 
expenditure, thermogenesis and physical activity), which imbalance the 
equation, will result in the accumulation of fat in the body (Spiegelman et al, 
2001). As an example, 3500 stored calories equals one pound of stored body 
fat.
The consequence of increasing stored body fat over time is obesity. In other 
words, obesity is characterised by an excess of adipose tissue.
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1.1.4 Body fat distribution in obesity
The perception that obese individuals differ and that it would be useful to 
distinguish between several types of obesity is not new. In the late 1940s 
Vague introduced the concept of male (android) and female (gynoid) patterns 
of fat distribution (Vague, 1947). He suggested that the topography of fat 
storage and body type were of prime importance in interpreting the health 
consequences of an obese state and that android obesity carried a greater 
health risk than gynoid obesity (Vague, 1956). It wasn’t until 40 years later 
that experimental evidence from both human and animal studies showed that 
the adipose tissue distribution is an important factor involved in the aetiology 
of type 2 diabetes and cardiovascular disease (Kissebah et al, 1982; Poulliot 
et al, 1992). The distribution is different between men and women, men being 
prone to accumulate their excess of energy in the abdominal region, more 
specifically in the intra-abdominal depot (visceral) whereas women show a 
selective deposition of adipose tissue in the gluteo-femoral region. This 
increase in visceral adipose tissue may play a significant role in the aetiology 
of metabolic complications increasing the risk of type 2 diabetes and 
cardiovascular diseases (Chan et al, 1994; Onat et al, 2004). Results of the 
Quebec Cardiovascular Study have shown that the cluster of metabolic 
disturbances observed among subjects with visceral obesity 
[hyperinsulinaemia, hyperapolipoprotein B and small, dense low-density 
lipoprotein (LDL) particles] is associated with a 20-fold increase in the risk of 
coronary heart disease in a sample of middle-aged men followed over 5 years 
(Despres, 2001). Selective mobilization of visceral adipose tissue in response 
to a weight loss program has been noted among viscerally obese patients,
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this reduction in visceral adipose tissue being associated with improvements 
in the lipoprotein-lipid profile and insulin sensitivity (Despres, 2001). The 
visceral and subcutaneous adipose tissue depots also differ in terms of 
activity and secretory function (Richelsen, 1991).
1.1.5 Assessment of obesity
To assess obesity properly, body fat content and fat topography need to be 
determined and compared to those obtained for an individual of a given age 
and gender class with valid sets of reference values (Shen et al, 2003). This 
has proven to be difficult in both research and clinical settings. At least three 
body fat phenotypes are of prime importance; total body fat content, upper 
body fat and abdominal visceral fat and these need to be evaluated in a 
laboratory environment, a clinic and population studies.
Body density derived from underwater weighing and converted to a proportion 
of fat in the body has been considered the gold standard procedure 
(Heymsfield, 1990). The method assumes that a two-compartment model of 
body composition to obtain a valid measure of body fat content. This is 
accurate when the density of fat free tissue is constant but when this 
component varies such as seen with exercise, ageing and some diseases, 
estimates of fat content may be slightly unreliable, mainly due to the variation 
in the conversion of body density to body fat content.
Dual emission X-ray absorptiometry (DEXA) is another method used to 
estimate body fat content (Kohrt, 1995). While this method can be used to 
quantify the absolute amount of fat on the trunk, the abdominal region, or any 
body segment, it cannot distinguish between subcutaneous and visceral fat. 
Other methods include isotopic dilution to assess body water, body potassium
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content to assess skeletal muscle mass, CT scanning and MRI examination at 
a large number of sites or over the whole body. Abdominal visceral fat can 
only be measured by CT scan or MRI (Ross et al, 2004). These methods are 
expensive and require elaborate instrumentation and thus confined for 
research purposes.
Simpler approaches of assessing obesity include the use of BMI as the 
surrogate for body fat content, the prediction of body fat from simple 
anthropometric measurements such as skinfolds and circumferences, and 
more recently, bioelectric impedance. Waist circumference and skinfolds give 
reasonable mean values for the prediction of visceral fat but are not very 
accurate for a given individual (Owen et al, 1999; Clasey et al, 1999). These 
methods, while less accurate than CT scans or MRI, are more suited for the 
clinic or the epidemiological research environment.
The number of fat cells can be estimated from measurements of total body fat 
and the average size of a fat cell. Rapid proliferation of adipocytes occurs 
soon after birth to 2 years of age, during late childhood and puberty. In some 
types of obesity a (hypercellular obesity) fat cell number increase 3-5 times 
above number (normal numbers being around 60 billion) and is associated 
with early or middle childhood and may also occur in adult life. In people more 
than 75% above their ideal body weight number of fat cells is usually higher 
than normal. Adult onset obesity involves enlargement of adipose tissue cells 
(hypertrophic obesity) and correlates with an android or truncal fat distribution 
and metabolic disorders such as glucose intolerance, hyperlipidaemia, 
hypertension and coronary artery disease (Walton, 1995).
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1.2 Adipose tissue
1.2.1 Adipose tissue deposition
Adipose tissues differ from many other tissues in that they occur in multiple 
dispersed sites around the body (Shen et al, 2003). In obesity increased 
amount of fat is found in the subcutaneous layers between the muscle and 
dermis as well as fat deposits around the heart, liver, kidneys and other 
visceral organs. The adipose tissue is considered an important component of 
the body’s system of energy balance and a storage depot. Around fifty 
percent of the tissue is composed of adipocytes, while the rest comprises of 
other cell types such as preadipocytes, endothelial cells, macrophages, blood 
vessels and neurons (Napolitano, 1965; Fain et al, 2002). They are found in 
the subcutaneous layers, which are located between skin and muscle, and 
intra-abdominal (visceral), which is distributed around the internal organs 
(Cinti, 2000). The tissue is composed of two types of cells, brown and white 
adipocytes, which express and secrete different proteins and vary in function. 
In humans significant amounts of brown adipose tissue are found only in the 
neonatal period. However, ordinary white fat may contain small islands of 
brown fat (Cinti, 1999). The data presented in this report are based upon the 
study of white adipose tissue.
1.2.2 Adipose tissue in obesity
There is some evidence indicating that the cellular composition of the adipose 
tissue changes in obesity (Wellen et al, 2003). Evidence exists for significant 
macrophage infiltration into adipose tissue in obesity (Xu et al, 2003) and may 
explain the inflammatory changes that occur in the obese state. Clusters of 
small, nucleated cells are present in obese adipose tissue. These clusters
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became larger and more numerous as the animals ages and gains weight. It 
has been shown that the largest class of genes significantly regulated in 
obesity, consists of macrophage and inflammatory genes in white adipose 
tissue (Fig 1.1). Although adipocyte precursors have potent phagocytic 
capacity and can be transformed into macrophage-like cells, there is the 
possibility that the cellular source of these inflammatory changes may not be 
only adipocytes, but also reticuloendothelial cells present in adipose tissue 
(Weisberg et al, 2003). Experiments in cultured clonal preadipocytes 
confirmed that the same inflammatory genes identified in the stromal-vascular 
fraction of white adipose tissue were not expressed in these cells (Xu et al, 
2003). Weisberg et al. also provide evidence that macrophage infiltration of 
adipose tissue is characteristic of human obesity, by determining that both 
BMI and average adipocyte size were significant predictors of macrophage 
accumulation in adipose tissue (Weisberg et al, 2003). These data bring the 
potential involvement of inflammation to the other pathologies associated with 
obesity. It is likely that a rich array of mechanistic and therapeutic 
developments will emerge from studies of the inflammatory pathways active in 
obesity and associated disorders.
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Figure 1.1: Cellular Composition of adipose tissue in obesity
In obesity adipose tissue is characterized by inflammation and macrophage infiltration. In obesity, low level secretion of TNFa by adipocytes can stimulate 
preadipocytes to produce monocyte chemoattractant protein-1 (MCP-1). Endothelial cells also secrete MCP-1 in response to cytokines. Both preadipocytes 
and endothelial cells could be responsible for attracting macrophages to adipose tissue. This could perpetuate a vicious cycle of macrophage recruitment, 
production of inflammatory cytokines, and impairment of adipocyte function (Wellen et al, 2003).
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1.3 The study of adipose tissue
The study of adipose tissue is in the main carried out in vitro using cell-lines or 
primary adipose tissue derived cells or in adipose tissue organ cultures. In 
humans in vivo investigation of adipose tissue involves microdialysis or 
arterio-venous difference studies (de la Pena et al, 2000). All of these 
techniques have their advantages and disadvantages and these are outlined 
below.
1.3.1 In vitro studies
In vitro studies on human adipose tissue and adipocytes involve organ culture 
of adipose tissue fragments or primary culture of adipocytes isolated by 
collagenase digestion of adipose tissue (Rodel, 1964; Fain et al, 2002). Organ 
culture, as applied to the adipose tissue, refers to intact fragments of adipose 
tissue placed in a complete, buffered culture medium that contains nutrients 
and electrolytes. The major strength of this method is the good maintenance 
of gene expression and adipocyte function within adipose tissue placed in 
organ culture for upto 2 weeks (Chajek-Shaul et al, 1996). Organ cultures 
have been used to assess the long-term effects of hormones on the 
metabolism of human, rat, ovine, bovine, murine and porcine tissue (frohlich
i
et al, 1972; Apple et al, 1992; keys et al, 1992; Baba et al, 1991). In all these 
species the long-term effects seem to reflect the known in vivo effects.
The advantage of primary culture of fat isolated by collagenase digestion over 
organ cultures is that only adipocytes are present here. Culture of fat cells is 
different from culture of newly differentiated adipocytes derived from stromal 
precursors. The latter generally remain multilocular, that is they have multiple 
lipid droplets, and there is some evidence that these cells are not fully
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differentiated. The chief advantage of the study of isolated adipocytes is that 
they are fully differentiated, unilocular adipocytes (Rodel, 1964).
In addition, there are also murine clonal lines available. Adipocyte precursor 
cell lines can be segregated into two classes, pluripotent fibroblasts and 
unipotent preadipocytes (Ntambi et al, 2000). The pluripotent fibroblasts can 
be converted to preadipose, premuscle and precartilage tissue upon its 
specific treatment. These multipotent fibroblasts act as good models for 
understanding the events responsible for cellular determination of the 
separate cell fates. The unipotent preadipocytes (such as Ob17 and its sub­
clone, 3T3-L1 and 3T3-F422A), have undergone determination and can either 
remain as preadipocytes or undergo conversion to adipose tissue (Ntambi et 
al, 2000). They are ideal for studying the molecular events responsible for the 
conversion of preadipocytes into adipocytes. The identification of specific 
developmental markers have also allowed for the comparison of the 
developmental programs of the various cell lines. The3T3-L1 and 3T3-F422A 
culture lines, derived from disaggregated Swiss 3T3 mouse embryos (Green 
and Kehinde 1974), are the most widely used culture models. The 3T3-L1 cell- 
line is one of the most well-characterized and reliable models for studying the 
conversion of preadipocytes into adipocytes. These cells are morphologically 
similar to fibroblastic preadipose cells found in the stroma of adipose tissue, 
and once differentiated, they exhibit virtually all of the characteristics 
associated with adipocytes present within the adipose tissue.
The advantage of using a cell-line is that it produces homogenous population 
of cells that are all at the same stage of differentiation. This allows for a 
definitive response to treatments. In addition, these cells can be passaged
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indefinitely, which provides a consistent source of preadipocytes for study 
(Ntambi et al, 2000). Confluent 3T3-L1 preadipocytes can be differentiated 
synchronously by a defined adipogenic cocktail. Maximal differentiation is 
achieved upon treatment with the combination of insulin, a glucocorticoid, an 
agent that elevates intracellular cAMP levels, and cosmic calf serum (Student 
et al, 1980). Insulin is known to act through the insulin-like growth factor 1 
(IGF-1) receptor. Dexamethasone (DEX), a synthetic glucocorticoid agonist, is 
traditionally used to stimulate the glucocorticoid receptor pathway. 
Isobutylmethylxanthine (IBMX), a cAMP-phosphodiesterase inhibitor, is 
traditionally used to stimulate the cAMP-dependent protein kinase pathway.
1.3.2 In vivo studies
Two techniques have been utilised for the study of human adipose tissue 
metabolism in vivo: microdialysis, and arterio-venous difference method. 
Microdialysis enables the concentration, of mainly water-soluble, molecules in 
the interstitial fluid to be measured (Arner and Bolinder 1991). Arterio-venous 
studies involve catheterization of the venous drainage from the subcutaneous 
abdominal adipose tissue (Arner, 1995). Blood obtained by this method shows 
all the characteristics expected of adipose tissue drainage. The characteristics 
of this tissue are quite distinct from those of the superficial, mainly skin, or the 
deep, mainly muscle, tissues of the forearm. The depot studied appears to be 
typical of adipose tissue as a whole, in terms of non-esterified fatty acid 
release. In comparison with the microdialysis technique, the arterio-venous 
difference method allows easier quantification of substrate uptake and 
release, and enables the study of hydrophobic molecules (e.g. fatty acids, 
triacylglycerol). On the other hand, it does not allow the study of more than
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one depot, or the local introduction of effectors of metabolism (e.g. adrenergic 
agents) (Frayn et al, 1993).
1.4 Adipose tissue derived factors
There has been a long-held belief that accumulation of adipose tissue may 
lead to increased risk of type 2 diabetes and cardiovascular disease because 
of associated metabolic alterations. For instance, non-esterified fatty acids 
(NEFA) are released from adipose tissue and with the increased adipose 
tissue mass of obesity, plasma NEFA concentrations are almost inevitably 
raised (Flatt et al, 1972; Opie et al, 1963). Elevated plasma NEFA 
concentrations may relate either directly or indirectly to other risk factors for 
cardiovascular disease (Frayn et al, 1996). In addition, as adipocytes enlarge 
with fat storage, they become less metabolically active and respond less well 
to insulin. An impaired ability of adipose tissue to respond rapidly to insulin 
and other hormones could be seen as a factor causing insulin resistance, and 
ultimately increased cardiovascular risk, through metabolic perturbations 
(Frayn, 2002).
However, currently, a central integrator of the metabolic programme is 
considered for adipocyte activity. In addition to the tissue acting as energy 
storage organ, with triacylglycerols acting as efficient energy reserve, the 
subcutaneous adipose tissue depots act as thermal insulation. The tissue is 
also essential for normal glucose homeostasis. The last few years have seen 
an explosion of research on alternative, non-metabolic links between adipose 
tissue, insulin resistance and cardiovascular disease. Indeed, current 
evidence suggests that the association between obesity and cardiovascular 
disease can be explained, at least in part, by novel signalling molecules,
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adipokines, emanating from, or expressed in, adipose tissue. The diversity of 
these factors includes enzymes such as lipoprotein lipase and hormone 
sensitive lipase, growth factors and cytokines such as tumour necrosis factor- 
a (TNF-a), interleukin-6 (IL-6) and heparin-binding epidermal growth factor­
like growth factor (HB-EGF) and several other hormone-like molecules 
involved in metabolism (leptin, adiponectin/Acrp30, resistin and acylation 
stimulation protein) (Mohamed-Ali et al, 1998)(Figure 1.2).
Figure 1.2: schematic view of biologically active fat-derived mediators
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It has been proposed that the secretion of molecules, such as leptin, 
adiponectin and IL-6 by adipose tissue, combined with the actions of adipose 
tissue-expressed TNFa in obesity, could underlie the association of insulin 
resistance with endothelial dysfunction, leading to CHD (Kern et al, 2001). 
The role(s) and regulation of these adipose tissue-derived molecules have 
been reviewed extensively and elegantly elsewhere (Mohamed-Ali et al, 1998; 
Kern et al, 2001) and for the purposes of this project two novel and distinct 
adipose tissue signals have been investigated with known associations with 
increased risk of type 2 diabetes and coronary heart disease:
• lnterleukin-6 (IL-6) and
• Asymmetric dimethyl arginine (ADMA), the endogenous inhibitor of 
nitric oxide (NO)
These signals will be discussed below.
1.4.1 lnterleukin-6
IL-6 is a proinflammatory cytokine with potent effects in host defence 
(Miossec, 1991). It is 22-28 kDa and is synthesized as a 212 amino acid (aa) 
precursor protein, with a 28 aa signal peptide and a 184 aa mature segment 
(Akira et al, 1993). IL-6 is expressed in adipose tissue and significant amounts 
of this cytokine are released, largely by the visceral adipose tissue, into the 
systemic circulation and its plasma levels increase with obesity (Fried et al, 
1998; Mohamed-Ali et al, 1997).
1.4.1.1 IL-6 receptors
The biological activities of IL-6 are initiated by binding of the ligand to a single 
receptor. The IL-6 receptor (IL-6R) comprises two chains, a ligand binding, 
predominantly extracytoplasmic chain (IL-6R; gp80) and the signal
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transducing gp130 chain (Hirano, 1998). The gp130 by itself has little or no 
IL-6 binding property, but it plays a part in signal transduction (Hirano et al,
1997). The binding of IL-6 to IL-6R is predominantly an extracellular process. 
This complex, IL-6/IL-6R, can be formed with either soluble or membrane- 
bound IL-6R (Kishimoto et al, 1992). The binding of IL-6 to IL-6R in the 
presence of gp130 leads to the formation of high affinity binding sites, gp130 
dimerisation and signal transduction (Hirano, 1998). Unlike in the case of 
TNFa, where the soluble receptors may function as inhibitors for the ligand, 
both recombinant and naturally produced circulating, soluble IL-6R (slL-6R) 
enable cells that express gp130 but not IL-6R to respond to IL-6 (Hirano,
1998). The signal transducing gp130 is abundantly expressed in most cell 
types, while IL-6R is expressed in a variety of cells in extremely low quantity 
(Kishimoto et al, 1992).
1.4.1.2 Acute and chronic release of IL-6
In addition to adipocytes/adipose tissue many different cells including 
macrophages, endothelial cells, smooth and skeletal muscle cells produce IL- 
6 (van-der-Poll et al, 1994; Purohit et al, 1995; Steensberg et al, 2001; 
Mohamed-Ali et al, 1998). However, the characteristics and regulation of IL-6 
production differs depending on cellular origin. During infection or in response 
to infectious stimuli, such as lipopolysaccharide (LPS), IL-6 is released from 
immune cells (e.g. monocytes and macrophages). Skeletal muscle cells on 
the other hand produce physiologically significant quantities of IL-6 in 
response to exercise (Pedersen et al, 2001).
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Both post-exercise and during infection the magnitude of the cytokine 
response is far greater but of a shorter duration, lasting hours or perhaps 
days, than that seen in metabolic diseases such as obesity. In obesity there is 
a chronic, low-level elevation in the circulating IL-6, probably of adipocyte 
origin (Fig 1.3). The metabolic consequences of acute, as opposed to chronic, 
elevations in circulating IL-6 levels are quite different, and as yet unresolved.
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Figure 1.3: Chronic and acute IL-6 release 
1.4.1.3 Effects of acute elevation in IL-6
In humans, acute elevation in IL-6 levels, as seen after intravenous 
administration, is associated with increased plasma glucose clearance rate 
and hyperinsulinaemia, indicating that IL-6 stimulates glucose uptake in vivo 
(Stouthard et al, 1995). It also increases basal and insulin-stimulated glucose
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uptake by 3T3.L1 and 3T3.F442A adipocytes in vitro (Stouthard et al, 1996). 
Stouthard et al. showed infusion of IL-6 to cause elevated serum triglycerides 
and NEFA concentrations (Stouthard et al, 1996). This hypertriglyceridaemia 
was caused by stimulation of hepatic triglyceride secretion and was 
independent of endogenous catecholamines (Metzger et al, 2001). IL-6 has 
been shown to stimulate insulin release from a hamster islet cell line (Shimizu 
et al, 2000). IL-6 stimulates glucose and fatty acid oxidation, and induces the 
release of glucagon and cortisol (Tsigos et al, 1997). IL-6 release from 
contracting skeletal muscle increases when muscle glycogen availability is 
reduced and increases glucose uptake. Also during exercise, IL-6 may have 
immunomodulatory effects, where it inhibits the expression of TNFa while 
inducing various anti-inflammatory cytokines such as interleukin-1 receptor 
antagonist (IL-1Ra) and interleukin-10 (IL-10) (Pedersen et al, 2003). IL-6 
infusion also increases plasma cortisol that indirectly causes a reduction in 
lypmphocyte numbers. Thus, collectively the data suggests that acute 
increases in IL-6 are beneficial, by increasing lipolysis, glucose availability 
and being anti-inflammatory.
1.4.1.4 Effects of chronic elevation of IL-6
Chronic elevations in circulating IL-6 concentrations are seen with increasing 
age, in Type 2 diabetes, CHD and obesity; conditions often associated with 
increases in adipose tissue mass (Goodpaster et al, 2002). In these 
conditions up to a third of the systemic IL-6 is adipose tissue-derived, with a 
significant proportion of this production being constitutive (Flower et al, 2003; 
Mohamed-Ali et al, 1997). That these levels may be adequate to induce the 
acute phase response may be concluded from elevated CRP also seen in
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obesity (McLaughlin et al, 2002). IL-6 has also been shown to inhibit the 
expression and secretion of the adipose tissue insulin sensitizer, adiponectin 
(Bruun et al, 2003; Fasshauer et al, 2003). IL-6, produced by adipose tissue, 
may also affect adipogenesis in a paracrine/autocrine fashion, and play a role 
in the pathogenesis of obesity. Indirect evidence for a possible role for IL-6 in 
adipogenesis comes from studies on the senescence accelerated mouse-P6, 
SAMP 6 (Kajkenova et al, 1997). These animals have been shown to have a 
higher percent body fat and ex vivo bone marrow cultures from these mice 
exhibited an increase in the number of colony-forming unit adipocytes, as well 
as an increase in the number of fully differentiated marrow adipocytes. Long­
term bone marrow cultures from SAMP 6 produced more IL-6. These data 
suggest a switch in the differentiation programme and support the existence 
of a reciprocal relationship between osteoblastogenesis and adipogenesis. 
This may explain the association of elevated systemic IL-6, decreased bone 
formation and the resulting osteopaenia with increased adiposity seen with 
advancing age in both animals and humans.
The data on the effect of IL-6 on lipolysis are also conflicting. In a study 
looking at the effect of food intake, sympathetic activation and lipolysis, it was 
reported that while TNFa correlated with lipolysis, IL-6 did not (Orban et al,
1999). Also in vitro studies have shown that in 3T3-L1 and 3T3-F442A 
adipocytes chronic exposure to IL-6 inhibits (B-adrenergically stimulated 
lipolysis (Clarke & Mohamed-Ali, 2003). However, previous reports have 
shown that IL-6 reduces lipoprotein lipase activity in adipose tissue and 
increases lipolysis (Mattacks et al, 1999). Therefore, while there is apparently
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a physiological difference between acute and chronic elevations in IL-6, the 
available data are not entirely clear and require further investigation.
1.4.1.5 IL-6 and metabolic disease
IL-6 may play a key role in several mechanisms that contribute to the 
development of CHD (Fig 1.4) (Yudkin et al, 2000). IL-6 is a powerful inducer 
of the hepatic acute phase response and several acute phase proteins, such 
as CRP and fibrinogen, are potent cardiovascular risk factors. Elevated 
concentrations of CRP are found in patients with acute coronary syndromes, 
and predict future risk in healthy subjects. Elevated levels of fibrinogen, with 
autocrine and paracrine activation of monocytes by IL-6 in the vessel wall 
contribute to the deposition of fibrin.
The acute phase response is associated with increased blood viscosity, 
platelet number and activity. IL-6 decreases lipoprotein lipase activity and 
monomeric lipoprotein lipase (inactive form) levels in plasma (Wallberg- 
Jonsson et al, 1996). Lipoprotein lipase has been shown to mediate the 
uptake of lipoproteins into cells, with the monomeric form inhibiting the uptake 
mediated by the dimeric lipoprotein lipase (Krapp et al, 1995). Therefore, the 
IL-6 mediated reduction in monomeric lipoprotein lipase may increase 
macrophage uptake of lipids. In fatty streaks and in the atheromatous ‘cap’ 
and ‘shoulder’ regions, macrophage foam cells and smooth muscle cells 
express IL-6, suggesting a role for this cytokine along with interleukin-1 p (IL- 
1 p) and TNFa , in the progression of atherosclerosis.
Circulating IL-6 stimulates the hypothalamo-pituitary-adrenal (HPA) axis, 
activation of which is associated with central obesity, hypertension and insulin 
resistance. IL-6 receptors are present in the hypothalamus, which supports a
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direct central role for this cytokine. IL-6 stimulates both thermogenesis and 
satiety, through a range of central effects, including prostaglandin synthesis 
and corticotrophin releasing hormone (CRH) release (Mastorakos et al, 1993). 
Thus IL-6 may be involved in the pathogenesis of CHD through a combination 
of autocrine, paracrine and endocrine mechanisms.
Although obesity increases circulating levels of IL-6, which contribute to some 
of the maladaptive consequences of obesity, the net effects of chronically 
increased circulating cytokine concentrations remain to be clarified.
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Figure 1.4: Reported correlations of interleukin-6 with CHD risk
Schematic representation of correlations between elevated systemic IL-6 
concentrations and various risk factors for coronary heart disease (CHD).It is 
postulated that IL-6 plays a role in the pathogenesis of CHD through a combination of 
autocrine, paracrine and endocrine mechanisms. IL-6 is a powerful inducer of the 
hepatic acute phase response and several acute phase proteins, such as CRP (C- 
reactive protein). Circulating IL-6 also stimulates the hypothalamic-pituitary-adrenal 
(HPA) axis, activation of which is associated with central obesity, hypertension and 
insulin resistance. It also has an effect on sympathetic nervous system (SNS) and 
catecholamine release (Yudkin et al, 2000)
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1.4.1.6 Mechanism of IL-6 secretion in adipocytes
The mechanism that sustains the basal secretion of adipocytes has not been 
determined. Adipocytes might be sensitive to IL-6-induced IL-6 release. There 
are data showing increased expression of IL-6 in differentiated 3T3.F442A 
adipocytes after treatment with IL-6. IL-1 [3 is a powerful stimulus of IL-6 
release from several cell types, including adipocytes and preadipocytes. IL-1 p 
is expressed by adipocytes and preadipocytes (Burysek et al, 1996; Auron et 
al, 1994), but does not appear to be an endocrine signal from adipose tissue 
in vivo. However it is feasible to suggest that IL-1 (3 expression is elevated in 
obesity and a COX-mediated prostaglandin pathway is responsible for the 
basal IL-6 release of adipose tissue.
1.4.1.6.a Prostaglandin E2 and COX pathway
Prostaglandin E2 (PGE2 ) modulates the production of inflammatory cytokines 
including IL-6 (Fieren et al, 1996). There are two cyclooxygenase (COX) 
enzymes, COX-1 and COX-2 (Gierse et al, 1995). These isozymes are 
responsible for the production of PGE2 . They are regulated by different 
mechanisms in the cell, but catalyse identical biosynthetic reactions. COX-1 
and COX-2 regulate cytokine synthesis in adipocytes by different roles. IL-6 
synthesis is stimulated by production of endogenous PGE2 . This effect is 
specifically linked to activation of COX-2 and not COX-1. Evidence for 
prostaglandin involvement in the regulation of IL-6 production comes from 
studies in various cell types (Takaoka et al, 1999; Fiebich et al, 2001).
In murine and human osteoblast and in human astrocytoma cells PGE2 
stimulates IL-6 production. They have shown that IL-1p-induced IL-6 
production is initiated by the production of PGE2. IL-1 p was found to induce
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the production of PGE2 and IL-6 in a dose-related fashion. PGE2 production 
was induced by lower concentrations of IL-1 p than those needed to induce the 
production of IL-6. Regarding the role of PGE2 in IL-1p-induced IL-6 
production, there have been some reports indicating that IL-6 production 
occurs after the production of PGE2 in other systems (Hinson et al, 1996; 
Calkins et al, 1988).
In murine peritoneal macrophages increasing release of IL-6 was found to 
correlate with increases in production of both PGE2 and PGI2, suggesting an 
autocrine function for these prostaglandins.
In mast cells PGE1 and PGE2 induce IL-6 production and inhibit TNFa 
production. In human peripheral blood monocytes, NCX4016 (NO-Aspirin), 
which is COX inhibitor, suppresses production of IL-6. Overall there is a 
positive association between endogenous PGE2 production and IL-6 release, 
with animal models also demonstrating that it is a stimulator of IL-6 production 
in vivo (Williams et al, 1997; Ma et al, 1997).
1.4.1.6.b Aspirin and COX inhibition
Aspirin or acetylsalicylic acid was first synthesised by Felix Hoffman in 1897 
and has now become the most commonly used non-steroidal anti­
inflammatory drug (NSAID) worldwide (Weissmann, 1991; Flower, 1985). 
Despite its long history and widespread use it was not until 1971 that Sir John 
Vane identified the enzyme cyclooxygenase (COX) as the target for NSAIDs, 
including aspirin (Vane, 1971). COX exists in two forms termed COX-1 and 
COX-2. Both forms release biologically active lipid mediators called 
prostaglandins but each COX has a distinct function. COX-1 is believed to 
regulate normal cell function whereas COX-2 is thought to release
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prostaglandins that initiate inflammation, fever and pain. Aspirin has many 
pharmacological actions (Claria et al, 1995).
The principal mechanism traditionally thought to be responsible for benefit of 
aspirin is inhibition of prostaglandin synthesis through irreversible acetylation 
of the COX-1 site (Rothe, 1975). This is the anti-thrombotic action of aspirin 
and subsequent inhibition of thrombus formation. The anti-inflammatory, anti­
tumour and neuroprotective properties of aspirin are less well understood but 
were believed to involve inhibition of COX-2 activity (Xu et al, 1994). However, 
aspirin is more active in inhibiting COX-1 activity and inhibits COX-2 activity 
only at high concentrations. The anti-inflammatory and anti-tumour actions of 
aspirin are likely to be mediated by mechanisms distinct from direct inhibition 
of COX activities. Several mechanisms have been reported. One mechanism 
that has attracted great attention is inhibition of nuclear factor (NF)-kB 
mediated gene expression (Kopp et al, 1994). However, the concentrations of 
salicylic acid (SA) and aspirin that are required to inhibit NFk- B mediated 
gene expression are in a range that is toxic to humans. It is therefore unlikely 
that aspirin and SA exert their anti-inflammatory action through NF-kB. Indeed 
aspirin and SA at such high concentrations have a broad non-specific effect 
on many cellular proteins. One study has shown that aspirin and sodium 
salicylate at therapeutic concentrations inhibited the activation of the COX-2 
promoter, reduced new mRNA synthesis and suppressed protein expression 
(Xu et al, 1994). It has been suggested that the therapeutic action of aspirin 
and salicylates are via suppression of C/EBP mediated gene expression 
(Saunders et al, 2001). It has also been shown that aspirin, both in vitro and in 
vivo, inhibits cytokine synthesis through a variety of molecular mechanisms
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(Wu, 2003). These beneficial effects of aspirin were especially significant in 
subjects with high circulating CRP levels. To date the effect of aspirin at the 
level of adipose tissue and specifically the adipose tissue release of IL-6 is not 
known.
1.4.2 Asymmetric Dimethylarginine (ADMA)
Recently, elevated plasma concentration of the naturally occurring NO 
synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) has been 
identified as a risk factor for type 2 diabetes and cardiovascular disease 
(Boger et al, 1998; Lin et al, 2002; Boger et al, 2004), and the circulating 
concentration of ADMA correlates closely with the degree of insulin resistance 
(Stuhlinger et al, 2002). ADMA and the inert isomer symmetric 
dimthethylarginine (SDMA) are released during the hydrolysis of proteins that 
contain arginine residues methylated by protein arginine methyltransferases 
(Clarke, 1993; McBride and Silver 2001) (Fig 1.5).
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The primary route of catabolism of ADMA is by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH) to form citrulline and dimethlyamine (Ogawa 
et al, 1989; Kimoto et al, 1995) (Fig 1.6). In contrast, SDMA is excreted 
unchanged in the urine and is not a NOS inhibitor.
Two isoforms of DDAH have been identified and their expression in several 
tissues reported (Leiper et al, 1999). The higher the DDAH activity, the lower 
the ADMA levels and inhibition of DDAH activity results in increased ADMA 
levels that may reach levels sufficient to inhibit NOS, and alter NO 
bioavailability.
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Figure 1.6: ADMA/DDAH pathway
Asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide (NO) 
synthase. ADMA, along with SDMA and L-NMMA, are synthesized by N- 
methyltransferases, a family of enzymes that methylate L-arginine residues 
within specific proteins. The primary and specific route of catabolism of ADMA 
is by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) to form 
citrulline and dimethylamine. A small proportion of ADMA is also excreted in 
the urine.
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ADMA and SDMA are the major circulating forms of methylarginines in 
humans and are present in the concentration range of 500nM-1 pM in plasma 
of healthy individuals (Leiper and Vallance 1999).
Given the role of DDAH in the regulation of ADMA degradation, for the second 
part of this project, we postulated that adipose tissue is a source of ADMA in 
obesity and interventions that alter adipose DDAH expression would be 
expected to modulate ADMA levels.
Previous studies have shown that increased plasma levels of ADMA are 
associated with risk factors for atherosclerosis such as hypercholesterolemia, 
ageing and hypertension (Voo et al, 2001; Maxwell et al, 1998). It has also 
been observed that elevated plasma ADMA levels are associated with 
impaired endothelium-dependent brachial artery vasodilatation in 
hypercholesterolemic individuals and intima media thickness in healthy 
subjects and is thought to be an important cause of endothelial cell 
dysfunction (Boger et al, 1998).
1.4.2.1 ADMA and Cardiovascular disease
ADMA, by blocking NO generation, initiates or encourages atherogenesis, 
plaque progression and plaque rupture. Some studies have shown that 
impairment of the NOS pathway independently predicts cardiovascular events 
(Schachinger et al, 2000; Suwaidi et al, 2000; Gokce et al, 2003).
There are data which show that increased levels of ADMA may contribute to 
endothelial dysfunction. It has been shown that patients with hypertension 
(Syrdacki et al, 1999), hyperlipidaemia (Boger et al, 1998), 
hyperhomocysteinemia (Sydow et al, 2003), coronary artery disease 
(Valkonen et al, 2001), peripheral arterial occlusive disease (Boger et al,
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1997), congestive heart failure (Usui et al, 2001), end-stage renal disease 
(Kielstein et al, 1999), pulmonary hypertension (Gorenflo et al, 2001) and 
stroke have elevated levels of ADMA in their plasma.
A causal relationship between increased ADMA levels and endothelial 
vasodilator dysfunction has been shown in some of these conditions. There is 
evidence that ADMA regulates vascular resistance in the human as well as 
the regulation of vascular structure and reactivity.
Infusion of ADMA in healthy volunteers increases blood pressure and 
vascular resistance and a fall in cardiac output and heart rate occur when its 
plasma concentration is increased above the physiological range (Achan et al, 
2003; Kielstein et al, 2004). Left ventricular hypertrophy is also a feature of 
prolonged NOS inhibition. ADMA also inhibits angiogenesis in animal models 
(Jang et al, 2000).
Elevated ADMA concentrations also seem to be a predictor for all-cause and 
cardiovascular mortality in patients with chronic renal insufficiency and acute 
coronary events. In non-smoking men with a history of coronary heart 
disease, those in the upper quartile of ADMA levels had a 4-fold increased 
risk of an acute coronary event (Valkonen et al, 2001).
1.4.2.2 ADMA and Diabetes
One of the precursors to Type 2 diabetes is insulin resistance, although it is 
not completely clear why this develops. Elevated ADMA levels have been 
found in animal models of type 1 and 2 diabetes (Xiong et al, 2003; Paiva et 
al, 2003). Insulin resistance is associated with raised levels of ADMA. In 
healthy volunteers without diabetes, ADMA levels were elevated in individuals 
who were insulin resistant (Stuhlinger et al, 2002). It has been shown that
48
blood levels of ADMA were directly related to their degree of insulin 
resistance, independent of other risk factors. However, rosiglitazone a 
hypoglycemic agent and an insulin sensitizer, with effects largely on adipose 
tissue, significantly improved sensitivity to insulin and reduced ADMA levels in 
the blood. Metformin another commonly used oral hypoglycemic agent, with 
mainly hepatic effects, and some structural similarities with ADMA also 
reduces systemic levels. The observed reductions in circulating ADMA with 
both rosiglitazone and metformin therapy could relate to the metabolic 
changes induced and be a direct consequence of improved insulin sensitivity 
(Stuhlinger et al, 2002; Vallance and Leiper 2004). Given the metabolic 
abnormalities of diabetic patients and their high risk for endothelium 
dysfunction, ADMA could represent an important linking factor for the 
impaired endothelium-dependent vascular function, insulin resistance and 
increased cardiovascular risks in Type II diabetes.
1.5 Aims of the study
Two novel cardiovascular risk factors, IL-6 and ADMA, with known 
associations with increased insulin resistance and endothelial dysfunction 
were investigated.
The first part of this project investigated the molecular mechanism of 
adipocyte and adipose tissue IL-6 release.
For this part of the project, the effect of prostaglandins, especially PGE2, and 
the cyclo-oxygenase (COX) pathway were investigated in the constitutive 
adipose IL-6 production in vivo and in vitro.
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Additionally, the molecular mechanisms by which COX inhibitors could 
regulate IL-6 release were examined ex vivo in adipose tissue and 
adipocytes.
The definition of the molecular mechanisms of cytokine secretion would allow 
more precise targeting of preventive approaches at high-risk individuals who 
may derive the greatest benefit from preventive treatment and the 
development of new therapeutic approaches to reduce risk.
Major aims of study on IL-6 release were:
• Effect of COX inhibition on basal secretion
• The prostaglandin receptors and their intracellualr mediators, Ca2+ and 
cAMP, regulating this release.
Other important COX mediated effects were also studied, namely 
adipogenesis.
The second part of the project set out to investigate the presence of 
ADMA/DDAH pathway in adipose tissue/adipocyte.
• In cell line
• In adipose tissue and
• Their regulation by diet and pharmacological agents
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CHAPTER 2: COX MEDIATED IL-6 SECRETION FROM 
ADIPOSE TISSUE AND ADIPOCYTES
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2.1 INTRODUCTION
There are close associations between interleukin-6 and various risk factors for 
type II diabetes and coronary heart disease, such as insulin resistance, high 
triglycerides, low HDL-cholesterol and elevated blood pressure (Yudkin et al,
2000).
IL-6 is expressed in and released by adipose tissue and its levels increase 
with increasing fat mass (Mohamed-Ali et al, 2000).
Normal circulating IL-6 levels in humans are in a range below 3pg/ml (D'Auria 
et al, 1997, Yamamura et al, 1998). Infection or injury can drastically, but 
acutely, increase these levels, up to greater than 200pg/ml (Aikawa et al, 
1996). Similar acute elevations are seen after exercise (Febbraio and 
Pedersen 2002). Plasma levels tend to return to baseline rapidly (<24 hours) 
once the stimulus is removed. However chronic elevation of IL-6 also occurs, 
notably in ageing, obesity, diabetes and coronary heart disease (CHD) 
(Yudkin et al, 2000). Concentrations rarely rise above 10 pg/ml, but levels 
remain elevated, and may have pathophysiological consequences.
In obesity a significant proportion of the circulating IL-6 is derived from 
adipose tissue (Mohamed-Ali et al, 2000). At least some of this release 
appears to be constitutive. The secretion of molecules, such as IL-6, by 
adipose tissue, could underlie the association between obesity, insulin 
resistance and endothelial dysfunction, leading to type II diabetes and CHD 
(Ridker et al, 1997; Ridker et al, 2000; Yudkin et al, 1999). Adipocytes utilise a 
variety of secretory pathways to release adipokines.
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Prostaglandins (PGs), specifically PGE2, modulate production of IL-6 from 
many cell-types (Williams et al, 1997). The first steps in prostaglandin 
biosynthesis are catalysed by cyclooxygenase (COX). COX-1 is constitutive 
and its levels are increased 2 to 4-fold by inflammatory stimuli. COX-2 is 
inducible and responsible for biosynthesis of inflammatory PGs and its levels 
increase 10 to 20-fold with inflammation (Katzung, 2001). Expression of PGE2 
receptors (EP 1-4) has been shown in adipose tissue. These receptors signal 
through unique intracellular pathways (Borglum et al, 1999). The EP1 receptor 
is coupled to phospholipase C and elevates (Ca2+)j. EP2 and EP4 receptors 
are coupled to Gas and elevate intracellular cAMP, while the EP3 receptor is 
coupled to Gai and decreases intracellular cAMP (Hatai, 2003).
2.2 AIM(S)
The aims of this study were to investigate the effect of the cyclo-oxygenase 
(COX) pathway on basal adipose IL-6 production and the molecular 
mechanisms involved in this secretion.
2.3 METHODS
2.3.1 Materials
3T3-L1 preadipocytes were a gift from Gokhan S Hotamisligil (University of 
Harvard, USA). Tri-Reagent was from Sigma (Dorset, UK) and Cambridge 
BioScience (Cambridge, UK). SYBR-Green reagents for real-time PCR 
analysis were purchased from Applied Biosystems (Warrington, UK). All 
oligonucleotides were synthesised by Oswel (Southampton, UK). Real-time 
PCR were carried out on an ABI-PRISM 7000 (Applied Biosystems). NS-398, 
PGE2 and the PGE2 receptor agonists (sulprostone, butaprost and PGE1
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alcohol) were obtained from Cayman and aspirin (acetyl salicylic acid) from 
Sigma chemical.
2.3.2 Adipocyte culture
3T3.L1 preadipocyte cell-lines were used in the preliminary experiments. The 
3T3.L1 cells were derived from the Swiss 3T3 celi-line prepared from 
desegregated 17-19 day-old Swiss 3T3 mouse embryos. 3T3.L1 
preadipocytes were seeded onto 6-well plates (Corning, High Wycombe, UK) 
at 6x104 cells/well. Cells were grown to confluence in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Gibco, Paisley, UK) supplemented with 10% bovine 
calf serum (BCS; Perbio, Paisley, UK), 200 units/ml penicillin and 50pg/ml 
streptomycin, at 37°C/10%CO2. At confluence (day 0) cells were differentiated 
by maintaining in DMEM/ cosmic calf serum (CCS, HyClone, Utah, USA) 
supplemented with insulin (5pg/ml), dexamethasone (1pM) and 
isobutylmethylxanthine (0.5mM) for 72h. At this stage the cells appeared 
rounded and contained tiny lipid droplets. The medium was then changed and 
cells allowed differentiating in DMEM/CCS containing only insulin (5pg/ml) 
until fully differentiated. The medium was changed every other day until >80% 
of the cells were differentiated.
2.3.2.1 Intervention
Differentiated adipocytes were exposed to different doses of non selective 
COX inhibitor, aspirin (5, 2, 1, 0.2 mM), or COX-2 selective inhibitor, NS-398 
(0.01, 0.1 and 1). These interventions were done in the presence or absence 
of IL-1 p (10ng.ml"1; IL-ip R&D Systems, Oxon, UK). After 24 h of treatment, 
culture media were collected to measure IL-6 or PGE2 levels. Cells were also 
collected for extraction of protein and RNA.
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Adipocytes were exposed to a variety of PGE2 receptor agonists: Sulprostone 
as an EP1/3 agonist, Butaprost as an EP2 agonist and PGE1 alcohol as an 
EP2/3/4 agonist at 1pM. Following 24 h exposure, media of cells were 
collected for analyses, as before.
2.3.3 Organ culture of adipose tissue
Subcutaneous and epididymal adipose tissue was removed from 12-week-old 
C57BL6/J mice animals. Subcutaneous adipose tissue was removed from 
dorsolumbar area, beneath the skin and without entering the abdominal 
cavity. Epididymal adipose tissue was removed from epididymal area in the 
intraabdominal cavity. The tissues were washed in PBS, cut into small pieces 
and weighed before the experiment.
2.3.3.1 Intervention
0.2g of tissue was incubated in 1.5 ml serum-free media (Cellgro, Hyclone, 
USA) for 5,10,24 and 48 hours at 37°C / 5% CO2 in the absence of any 
additives (as a basal control) or with added COX inhibitors (aspirin: 0.2, 1, 2 
and 5mM; NS-398: 0.01, 0.1 and 1pM). At the end of the incubation, media 
was removed and retained for assay and the tissue was snap frozen in liquid 
N2 and stored at -80°C for protein extraction.
2.3.4 Assays
Supernatants from cell culture and explants were assayed using a 
commercially available IL-6 ELISA (R&D Systems, Oxon, UK) for interlukin-6 
and EIA (Cayman) to measure PGE2.
The results from the assay were divided by the weight of fat tissue to give the 
amount of IL-6 release per gram of tissue.
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2.3.5 Cell lysate preparation, protein estimation and SDS-PAGE
2.3.5.1 Cell lysate preparation
Protein was isolated from 0.2g of frozen adipose tissue. The tissue was 
crushed, digested and homogenised with RIPA buffer (1x PBS, containing 
0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40 supplemented with 
protease inhibitors cocktail tablet (1 tablet/10ml) (Complete, Roche Diagnostic 
Gmbh, Mannhein, Germany). Protease inhibitor contained 3.0mg Antipain- 
HCI, 0.5mg Bestatin, 1.0mg Chymostatin, 3.0mg E-64, 0.5mg Leupeptin, 
0.5mg Pepstatin, 3.0mg Phosphoaramidon, 20.0mg Pefablock SC, 10.0mg 
EDTA and 0.5mg Aptotinin. After 15 minutes centrifuging at 14000rpm, the 
infranatant was recovered and stored at -80°C for protein estimation and 
SDS- PAGE analysis.
2.3.5.2 Protein estimation
Lowry method was used to estimate total protein content (Tornqvist et al, 
1975). Standard samples were prepared in buffer with BSA at concentrations 
of 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.0625 mg/ml and 
0.0313 mg/ml. 5 pi of sample or standard were added to a 96-well plate. After 
15 minutes incubation with Bio-Rad protein assay reagent A, 200 pi reagent B 
were added. They were incubated for a further 15 minutes. Absorbance was 
measured at 650 nm using plate-reader (Spectra Max 250).
2.3.5.3 SDS-PAGE analysis.
Sodium dodecil sulphate (SDS) polyacrylamide separating gel was used. 
Separating gel was prepared with 10% polyacrylamide, 0.375 M Tris-HCI pH 
8.8, 0.1% SDS, 0.05% ammonium persulphate and 0.05% TEMED. The gel
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was added by a stacking gel containing of 5% polyacrylamide, 0.125 M Tris- 
HCI pH 6.8, 0.1% SDS, 0.05% ammonium persulphate and 0.05% TEMED.
25 pg of sample was added in loading buffer (6% SDS, 6% 
2-mercaptoethanol, 40% sucrose, 0.2% bromophenol blue in 0.125 M 
Tris-HCI, pH 6.8). The mixture was boiled for three minutes before loading 
onto the gel.
Running buffer (20 mM Tris-base, 200 mM glycine and 0.1% SDS) was added 
into the electrophoresis tank. Then the gels were run at 80 Volt for 
approximately 90 minutes until enough separation had occurred.
2.3.6 Western analysis
After removing the gel, it soaked in transfer buffer (20 mM Tris-base, 200 mM 
glycine plus 200ml methanol of total of 1000ml distilled water) for 20 minutes. 
PVDF membrane was activated by incubation in methanol, distilled water and 
transfer buffer for 5 seconds, 5 and 10 minutes respectively. Protein was 
transferred from the gel to the membrane by using semi-dry blot method 
(Multiphor II, Pharmacia).
16 sheets of filter paper were soaked in transfer buffer prior to transfer. Eight 
of them were placed on the negative electrode, followed by PVDF with the gel 
on the top of them. This assembly was sandwiched with a further eight sheets 
of soaked filter paper covered on the gel, before the positive electrode was 
placed upon them.
The gels were blotted electrophoretically onto PVDF membranes at the 
voltage of 25 Volt for 25 minutes. Following the blotting process, the 
membrane was blocked with 5% non-fat dried milk in PBST (Phosphate Buffer 
Salin plus 0.1% Tween 20) for one hour at room temperature and washed
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three times in PBST at 10 minutes per wash. The blots were probed overnight 
at 4°C with commercially available rabbit polyclonal antibodies against COX-2 
(Cayman) diluted 1:5000 in PBST milk.
The membrane was washed three times in PBST (10 minutes per wash) and 
secondary antibody consisting of goat anti-rabbit IgG conjugated to horse­
radish peroxidase (Amersham Bioscience) was added at 1:5000 dilution in 
PBST and incubated for one hour at room temperature. The membrane was 
washed four times and incubated in enhanced chemiluminescence (ECL) plus 
reagent for two minutes. Antigen-antibody complexes were detected by 
chemiluminescence with an ECL kit and blots exposed from five seconds to 
two minutes to high performance chemiluminescence film (Kodak).
2.3.7 RNA isolation
RNA was isolated from cultured adipocytes. Tri-reagent (400 pi to each well of 
a 6-well plate or 1 ml to 25 cm2 flasks) was added, mixed and incubated at 
room temperature for five minutes. Repeated pipetting was used to 
homogenise the cells. 200 pi DEPC-chloroform per 1 ml Tri-reagent was 
added. Samples were mixed by vortexing and incubated on ice for five 
minutes. Samples were then centrifuged at 12000 x g for 15 minutes at 4°C 
and the aqueous layer removed.
A 1/io volume of DEPC-isopropanol was added, vortexed and centrifuged at 
12000 x g for 10 minutes at 4°C. The upper layer was removed to another 
tube and DEPC-isopropanol was added (500 pi isopropanol per 1 ml Tri­
reagent). Samples were incubated overnight at -20°C, and subsequently 
centrifuged at 14000 x g for 30 minutes at 4°C. At this stage, a small pellet 
was visible in each tube. All liquid was removed and the pellet washed in
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800 jliI of 75% DEPC-ethanol. Following further centrifugation at 14000 x g for 
10 minutes at 4°C the pellet was air-dried and reconstituted in 50 pi nuclease- 
free water.
2.3.8 cDNA synthesis
4 pi of the sample was diluted in 1 ml DEPC water to measure O D 26o and 
O D 28o. DEPC-water was used as a blank for each measurement. At O D 26o an 
optical density of one corresponds to approximately 40 pg/ml RNA in an 
undiluted sample. Therefore, with the above dilution, an O D  of one would 
indicate 10 mg/ml. Thus, multiplication of the measured O D 26o by 10 provides 
the RNA concentration in pg/pl. Purity of the RNA preparation was assessed 
as a ratio of O D 26o/O D 28o, where a value of two indicated pure RNA, and a 
reading between 1.7 and 2.1 was considered acceptable purity.
5 pg RNA was used to synthesise complementary DNA (cDNA). To 5 pg 
RNA, a mixture of 7 pi 5x reverse transcriptase buffer, 3.5 pi 0.1 M DTT, 2 pi 
20 mM dNTP, 1 pi 40 U/pl RNAse inhibitor and 0.5 pi 50 pmol random 
oligonucleotide primers were added. Total volume of 33 pi was prepared by 
using nuclease-free water. The mixture was heated to 65°C for 10 minutes. 
Then, 2 pi reverse transcriptase (200 U/pl) was added on ice, and the sample 
incubated at 42°C for 90 minutes. cDNA samples were stored at -20°C until 
required for PCR analysis.
2.3.9 Taq-man Real-time PCR Analysis
Each primer sequence for Taq-man® PCR analysis was designed by using the 
software package Primer Express. Primers with the concentration of 80 
nmol/ml were prepared, and forward and reverse primers were mixed equally
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to give a final concentration of 40 nmol/ml of each primer. Reconstituted 
primers were stored at -20°C.
25 pi total volume of samples per well was run in duplicate. This volume 
consisted of 1.25 pi specific primer, 12.5 pi SYBR-green solution, 1 pi cDNA 
and 10.25 pi nuclease-free water. A negative control consisting of nuclease- 
free water in place of cDNA for each primer was included in PCR reaction. 
GAPDH as a control mRNA was also run in duplicate. A Standard procedure 
specified by the ABI Prism 7000 software was used for reactions. 
Amplification conditions using this method remain constant independent of the 
primer sequences used.
Data were obtained from a minimum of at least five separate experiments. 
Data analysis was done by using the 2'MCt method which was described by 
Livak and Schmittgen for relative quantification of real-time PCR (Livak and 
Schmittgen 2001). The data are expressed as changes in expression 
compared to an arbitrary baseline (described for each individual message 
investigated).
2.3.10 Plasma membrane Ca channels
This part of experiment was done in collaboration with Dr Gui-ping Sui in 
Institute of Urology at University College London.
2.3.10.1 Electrophysiological recordings
Membrane currents were recorded by voltage-clamp in the whole-cell 
configuration, using an Axopatch 1D system (Axon Instruments Inc.). Fire- 
polished glass pipettes (3-5 Mn.) were used back-filled with a Cs+-based 
solution to suppress outward K+ currents (see below). Cells were superfused 
with oxygenated Tyrode’s at 36°C at a flow rate 1.0ml/min. Voltage-clamp
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pulses were generated and data were captured using a Digidata 1200 (Axon 
Instruments) interfaced to a computer. Currents were sampled at 2 kHz and 
low-pass filtered at 1 kHz. No leak subtraction was used. Cell capacitance 
was recorded on membrane rupture with the patch pipette. Data were 
analysed using the pCIamp 8.0 system (Axon Instruments). Cells were held at 
either -100 or -40 mV for 2 seconds, before 800 ms step pulses were applied 
from a pre-conditioning pulse at -60 mV for 1 ms. Step pulses were between 
-100 and +50 mV in 10 mV increments
Peak inward current magnitude was plotted as a function of test potential to 
generate current-voltage (i-v ) relationships. The reversal potential, Vr, was 
calculated by extrapolating the right-hand limb of the linear portion of the i-v  
relationship to the voltage axis (see figure 2.4). The slope of the line was 
used as an estimate of maximum conductance, g max (units S, Siemens). All 
current and conductance values are normalised to unit cell capacitance. 
Channel conductance, g, at more negative voltages was calculated from g  =  
i/(V-Vr). Activation curves were fitted to the Boltzmann relationship 
g/gmax=1/(1 +exp(-(\AV'o.5)/kd)); where V0.5 is the test potential when g  =  
0.5gmax, Vd and kt are constants. The inactivation kinetics of peak inward 
current were investigated by holding the cell at voltages between -120 to 
+50mV, at 10mV increments, for 2 seconds, and applying a test pulse from -  
60 (1ms) to the voltage at which maximum inward current was attained for 
each cell (between -30 or -10 mV) for 800ms. The relationship between i/imax 
and holding potentials of Vh was fitted to the relationship: ///max =1/(1+exp((\/h- 
Vb.sVkf)). /max was attained at the most negative holding potentials, Vb.5 is the
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membrane potential when / = 0.5/max, k\ is a constant. All data values are 
given as mean ±SD.
Cells were superfused with Tyrode’s solution (mM): NaCI 118; NaHC03 24; 
KCI 4.0; MgCl2.6H20 1.0; NahhPO^hfeO 0.4; glucose 6.1; Na pyruvate 5.0; 
pH 7.4±0.03 gassed with 5% CO2 & 95% O2 . For Ca-free Tyrode’s solution, 
CaCI2 was replaced by equimolar MgCI2 plus 0.12 mM EGTA. NiCI2 was 
stored as a 100 mM stock solution in de-ionised water and diluted in Tyrode’s 
solution. Patch pipettes were filled with (mM) CsCI 20; aspartic acid 110; 
MgCI2.6H20  5.45; Na2ATP 5.0; Na4GTP.2H20  0.3; EGTA 5.0, HEPES 5.0; 
pH 7.1 adjusted with CsOH. All chemicals were obtained from Sigma.
2.3.10.2 Fluorescence Confocal imaging
Intracellular Ca2+ release, at the single cell level, was measured using 
standard [Ca2+]c fluorimetry and imaging techniques to explore the [Ca2+1 
signalling pathways in differentiated adipocytes. Fluorescence imaging, on the 
confocal system (Zeiss 510 LSM), with calcium indicators (fluo-4) was used to 
image [Ca2+]j signals generated. Differentiated 3T3.L1 adipocytes were loaded 
with Fluo-4 (0.25nM) with 2% pluronic (detergent). Cells were washed and 
ATP (1-100 pM) or IL-1 p(1 Ong/ml) added.
2.3.11 Statistical Analyses
Data were analysed using the SPSS version 6.0 statistical package 
(Statistical Package for the Social Sciences, SPSS UK Ltd, Chertsey, UK). 
Data are presented as means and standard error of means or interquartile 
ranges. Significance was defined as 2-tailed p<0.05.
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2.4 RESULTS
2.4.1 COX expression and IL-6 release in adipose tissue organ cultures
In organ cultures of mouse adipose tissue from sub-cutaneous (dorsal- 
lumbar) and visceral (epididymal) depots COX-2 protein was constitutively 
expressed and remained elevated for up to 48h, with leveis highest at 24h of 
incubation (Figure 2.1a). Culture media surrounding these tissues showed 
significant accumulation of IL-6 with a similar time course to the expression of 
COX-2, with the highest levels after 24 hours (Figure 2.1b).
Western Blot Sub-cutaneous Epididymal
< ► < ►
Hours 5 10 24 48 5 10 24 48
Figure 2.1a: Time course expression of COX-2 protein in subcutaneous 
and epididymal adipose tissue
Constitutive COX-2 protein expression in sub-cutaneous and epididymal 
murine adipose tissue explants was seen by western blot analysis.
Expression remained elevated for up to 48 hours, with it’s a peak at 24 hours.
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Figure 2.1b. Time course release of IL-6 in subcutaneous and epididymal 
adipose tissue
IL-6 release from sub-cutaneous and epididymal murine adipose tissue 
explants up to 48 hours with its peak at 24 hours. The release of IL-6 was 
calculated based on per gram release of tissue. Data shown as mean±SD, 
n=12
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Figure 2.2: Effect of aspirin on IL-6 release in subcutaneous and 
epididymal adipose tissue explants
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Figure 2.2 shows that after 5 hours incubation the IL-6 release from both sub­
cutaneous and epididymal adipose tissue was decreased significantly by the 
non-selective COX inhibitor, aspirin at 5 mM, but not at 0.2 mM.
Furthermore, a selective COX-2 inhibitor, NS-398 ( 1 pM), also reduced 
release (by 34.0 -  62.0 %, n=8, p <0.05) (Fig 2.3)
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Figure 2.3: Effect of NS-398 (COX-2 selective inhibitor) on IL-6 release in 
subcutaneous and epididymal adipose tissue explants
Figure shows dose dependent inhibitory effect of a selective COX 2 inhibitor 
(NS 398, 0.01 and 0.1 pM) on IL-6 release in murine subcutaneous and 
epididymal adipose tissue explants. (Data are presented as mean±SD, n=12)
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2.4.2 IL-6 release from differentiated 3T3-L1 adipocytes
In differentiated adipocytes IL1p increased IL-6 release (Flower et al, 2003; 
Crofford, 1995) and induced the expression of COX-2 protein. In these cells 
aspirin inhibited the induction of IL-6 release (0.2, 1.0 and 2.0 mM) (Figure 
2.4), with higher doses of aspirin (2.0mM) being associated with a greater 
reduction in IL-6 release compared to low doses of aspirin (0.2 and 1 .OmM).
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Figure 2.4: Effect of aspirin on IL-6 release of IL-1p induced 3T3-L1 
differentiated adipocytes
Dose dependent inhibitory effect of aspirin (0.2, 1.0 and 2.0 mM) on IL-1(3- 
induced (10 ng/ml) IL-6 release in differentiated 3T3L1 adipocytes (data shown 
as mean±SD; n=12).
2.4.3 PGE2 induced IL-6 release in 3T3-L1 adipocytes
In both 3T3L1 and in adipose tissue explants PGE2 accumulated in the media 
over a 24h time period, with a positive, significant correlation between IL-6
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and PGE2 concentrations (r=0.67, p<0.01, n=11 sample pairs), as seen 
previously by others (Fain et al, 2001; Fain et al, 2002).
Exogenously added PGE2 also elicited a significant IL-6 output that was both 
dose and time-dependent (figure 2.4). Peak release of IL-6 from adipocytes 
was observed following 24 hours incubation. There was significantly higher 
release of IL-6 in cells treated with 1 and 2 pM PGE2 compared to those with 
lower concentrations (0.01 and 0.1 pM). This effect was evident at all time 
points.
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Figure 2.5: Effect of PGE2 on IL-6 release of differentiated adipocytes in 
a dose and time-dependent manner
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2.4.4 Intracellular mediators of PGE2 signalling - Ca2+ and cAMP- 
dependent pathways
PGE2 signalling could be mediated by several EP receptors that either elevate 
[Ca2+]i (EP1), or modulate intracellular cAMP levels (EP2, 3 and 4). First, the 
routes of Ca2+ regulation in differentiated 3T3-L1 adipocytes were characterised 
to determine if Ca2+-sensitive pathways may regulate IL-6 release.
Ca2+ currents were measured under voltage-clamp in 18 cells. Large transient 
inward currents were seen when a cell was depolarised from -100 to between 
-50 and 0 mV, using a Cs+-filled pipette (Figure 2.6A). The current was 
reversibly abolished when extracellular Ca was reduced. The inward current- 
voltage (i-v) relationship is shown as the test potential was varied from a 
holding potential o f-100 mV in 10 mV steps to +50 mV (Figure 2.6B). Current 
peaked at -40 to -30 mV and reversed at about +50 mV. Shown also is the i-v 
from a holding potential of -40 mV when no inward current was recorded on 
further depolarisation.
The voltage-dependence of inward current is similar to that of T-type Ca2+ 
channels recorded from other cell types and the lack of inward current at a 
holding potential of -40 mV (figure 2.6B) suggest an absence of L-type Ca2+ 
current. T-type channels are blocked by sub-miHimolar concentrations of Ni2+ 
and this was tested in these cells. Figure 2.6C shows that the inward current 
was reversibly abolished by 300 pM NiC^. Finally the voltage-dependence of 
current activation and inactivation were determined (see Methods) to 
characterise further the currents. Figure 2.6D shows averaged curves with half- 
maximal voltages of activation and inactivation of -48.0±0.2 mV (n=14) and - 
72.9±0.3 mV (n=15) respectively.
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The expression of T-type Ca channel was confirmed in 3T3L1 preadipocytes 
and differentiated adipocytes at the mRNA level, by using Taq-man real time 
PCR. Both preadipocytes and differentiated adipocytes expressed T-type Ca 
channels.
Figure 2.6: Inward currents recorded in isolated 3T3-L1 cells
Figure 2.6A: Inward currents recorded from a holding potential o f -100 mV to 
values between -50  and 0 mV, using a Cs+-filled patch pipette.
Figure 2.6B: current-voltage relationships of the inward current recorded from 
a holding potential of e ither-100 mV (squares) or -40  mV (circles).
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Figure 2.6C: Inward current recorded from a 3T3-L1 cell after five minutes 
exposure to 300 pM NiCh: control traces before exposure and 10 minutes 
after washout from NiCb are also shown. Step depolarisation from -100 to -  
30 mV.
Figure 2.6D: Activation (circles) and inactivation (squares) curves for the 
inward current. Curves were fitted to the equation in the Methods. Mean data 
± SD in parts B and D.
Intracellular Ca2+ release pathways were also measured using 
epifluorescence microscopy. The fluorochrome was excluded from lipid
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droplets and thus represented cytoplasmic changes of [Ca2+]. Figure 2.7 
shows that ATP (1-100 mM) generated a Ca2+ transient that persisted in Ca2+- 
free superfusate, which suggests that Ca2+ release was from intracellular 
stores. The mobilization of stored Ca2+ from the endoplasmic reticulum (ER) 
through inositol 1,4,5-triphosphate (IP3) or ryanodine receptors (RyR) was 
also characterised. In adipocytes the Fluo-4 dye was excluded from the lipid 
droplets. Within a few seconds after the addition ATP-induced waves were 
observed (Figure 2.7). There was considerable heterogeneity in the nature of 
the [Ca2+]j signal observed, with some cells being less responsive, some 
demonstrating oscillations and waves. Also some cells demonstrated multiple 
[Ca2+]j waves emanating from different points of the cell. Thapsigargin, an 
inhibitor of the ER Ca2+-ATPase in Ca2+-free media, initially slowed recovery 
from ATP evoked [Ca2+]j responses and eventually abolished them, strongly 
suggesting that the signal arises through mobilisation of ER Ca2+. ATP 
treatment induced elevation in intracellular [Ca2+]j, but did not alter IL-6 
production. Caffeine, an agonist of RyRs, also caused no change in IL-6 
release from adipocytes, but arachidonic acid, an IP3R inhibitor, induced IL-6 
release. Treatment of adipocytes with IL-1p had no effect on the [Ca2+]j 
responses. IL-6 release from 3T3-L1 adipocytes was measured in the culture 
supernatant before and after the addition of 100 pM NiCh and 1.0 and 10.0 
mM ATP. However, neither of the two agents affected the rate of release. 
Treatment of 3T3-L1 and isolated primary adipocytes for four hours with the 
cell permeable analogue of cAMP, dibutyryl cAMP (10 mM) significantly 
increased IL-6 secretion. Control 18.5(15.7-35.5}; dbcAMP 134.7(71.1- 
171.2} pg.ml-1 p<0.001).
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Figure 2.6F: Changes in intracellular Ca in ATP treated 3T3L1 adipocytes
These figures are a representation of changes in intracellular calcium in two 
different adipocytes following ATP treatment. Cell 1 RO (region of interest) 
shows a sustained elevation in intracellular Ca while Cell 2 shows calcium 
waves.
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2.4.5 EP receptor agonists and IL-6 release
The results thus far suggest that cAMP, but not Ca2+-dependent pathways 
mediate IL-6 release from adipocytes. Therefore EP receptors utilising cAMP 
as a second messenger should regulate cytokine production. This hypothesis 
was tested by measuring IL-6 release in the presence of EP receptor agonists 
that raise intracellular [Ca2+], such as the EP 1/3 agonist sulprostone, or those 
that raise cellular cAMP, such as the EP2 agonist butaprost, or the mixed 
EP2/3/4 agonist PGE1 alcohol. Figure 2.8 shows that sulprostone (1 pM) had 
no significant effect on IL-6 release. However both butaprost and PGE1 
alcohol (1 pM) significantly augmented release.
i/>
o>o
inO
0.8
Io>
c
0.60)(/)ro<u
©
;  04
0.2
0.0
PGEIalcControl Sulprostone Butaprost
EP receptor agonist (1pM)
Figure 2.8: Effect of EP receptor agonists on IL-6 release in 
differentiated 3T3-L1 adipocytes
There was no significant change in IL-6 release from differentiated 3T3L1 
adipocytes in response to Sulprostone (EP 1/3 agonist; 1pM). However both 
Butaprost (EP2 agonist; 1pM) and specifically PGE1 alcohol (PGE1 alcohol: 
EP2/3/4 agonist; 1pM) significantly augmented release.
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2.5 DISCUSSION
Obesity is associated with elevated circulating interleukin-6 (IL-6) 
concentrations, derived from adipose tissue, a proportion of which is 
constitutive. This study aimed to investigate the effect of the cyclo-oxygenase 
(COX) pathway on basal IL-6 production from adipocytes and the molecular 
mechanisms involved in this secretion. In adipose tissue explants there was 
basal expression of COX-2 and a positive correlation between prostaglandin 
E2 (PGE2) and IL-6 levels in the surrounding medium. Aspirin (5 mM) and the 
selective COX-2 inhibitor, NS-398 (^1 pM) attenuated IL-6 release. In 3T3-L1 
adipocytes PGE2 increased IL-6 secretion. The cellular pathways underlying 
IL-6 secretion were investigated. Ni-sensitive T-type Ca2+ channels were 
demonstrated in 3T3-L1 cells and intracellular Ca2+ release via ryanodine 
receptors was generated by ATP. However, neither NiCh nor ATP had any 
effect on IL-6 production.
Prostaglandins signal via EP receptors (EPs). EP-1 activation signals through 
a rise of the intracellular [Ca2+], but the EP-1 agonist, sulprostone, did not alter 
IL-6 release. However, the mixed EP-2/4 agonist, prostaglandin-E1 alcohol, 
and to a lesser extent the EP-2 agonist butaprost, which raise intracellular 
cAMP, significantly augmented IL-6 release, as did the membrane permeable 
cAMP analogue, dibutyryl cAMP (10 mM). Basal IL-6 release occurred 
through a golgi-dependant process which was transcriptionally regulated, but 
IL-6 was not stored in adipocytes prior to release. Thus, basal adipose tissue 
IL-6 secretion is mediated by COX-2 mediated PGE2 generation. Release is 
independent of changes to intracellular [Ca2+], but depends on cAMP and is 
mediated by EP4 receptors.
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Previous data that IL-1p stimulates the production of IL-6 in 3T3L1 adipocytes 
were confirmed. Simultaneously, IL-6 production is induced by the production 
of PGE2. It has been shown that there is a dose dependent effect of ILip on 
IL-6 secretion in adipocytes. IL1p increased COX2 expression in 3T3L1 
adipocytes. Similarly, PGE2 increased IL-6 secretion in adipocytes in a dose- 
dependent and time-dependant manner.
It was shown constitutive COX-2 protein expression in sub-cutaneous and 
intra-abdominal adipose tissue explants that increased over 48h incubation, 
(peak at 24h). Basal IL-6 secretion mimics the COX-2 expression and 
correlates with endogenous PGE2 production. Furthermore, COX inhibition 
significantly reduced IL-6 production from adipose tissue, as well as the IL-1 p 
induced IL-6 secretion in differentiated 3T3-L1 adipocytes.
In summary PGE2 stimulates IL-6 synthesis in 3T3.L1 adipocytes. Exogenous 
PGE2 and EP agonists induce IL-6 via EP4 receptors (present in AT- SV & 
macrophages) and elevation in intracellular cAMP.
Understanding the specific pathway of adipose IL-6 release would allow 
targeted modulation of this function.
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CHAPTER 3: ADIPOGENESIS
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3.1 INTRODUCTION
Adipogenesis, or the conversion of preadipocytes to adipocytes, has been 
one of the most intensely studied models of cellular differentiation (Rosen and 
Spiegelman 2000). In this process undifferentiated, precursor, fibroblast-like 
cells are converted to cells with adipocyte morphology and functional 
capability (Napolitano, 1963). The adipose tissue plays a central role in 
controlling energy metabolism within the organism. The study of how fat cells 
develop and are controlled is germane because of their role in obesity.
The study of adipogenesis has been facilitated by the availability of reliable in 
vitro cellular models (Rosen et al. 2000). Adipocytes are recognized 
increasingly as major players in a variety of physiological and 
pathophysiological states, such as obesity and type 2 diabetes (Rosen, 2002). 
Research attention has shifted from evaluating fat storage mechanisms to 
studying the creation and proliferation of adipose tissue in the body. 
Understanding the process by which cells differentiate into fat and the 
mechanisms involved in this pathway may hold greater promise for controlling 
and eliminating obesity and its co morbidities (Gregoire et al, 1998) 
Experiments using in vitro murine models of adipogenesis, which include the 
3T3-L1 and 3T3-F442A lines, have illustrated the transcriptional cascade that 
promotes fat cell differentiation (Rosen et al. 2000). Though major advances 
in the understanding of adipogenesis have been made, the details are still not 
entirely elucidated. Recent studies suggest that some of disorders related to 
obesity may be linked to a breakdown in the regulatory mechanisms that 
control the expression of metabolic genes in mature adipocytes. Some 
progress toward an understanding of these processes has come from studies
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involving the identification of transcription factors that regulate adipogenesis 
(Rosen et al, 2000).
3.1.1 Adipogenic transcription factors
Differentiation of adipogenic precursor cells into mature adipocytes is a 
complex phenomenon. It follows a highly ordered sequence (Fajas, 2003). 
One of the first steps in the process of adipogenesis is the re-entry of growth- 
arrested preadipocytes into the cell cycle and the completion of several 
rounds of clonal expansion.
Many aspects of adipogenesis can be described as a cascade of gene 
expression characterized by an ordered expression of adipocyte-specific 
genes, triggered by a set of interacting transcription factors (Rosen et al. 
2000). The most important transcription factors involved in this process are 
the y forms of peroxisome proliferator activated receptors (PPAR y1 and y2) 
and the various members of the CCAAT enhancer binding proteins (C/EBP) 
(Wu et al, 1995; Umek et al, 1991). PPARy2 and C/EBPa are major 
controllers in the process of fat cell development and growth (McNeel and 
Mersmann 2000). They regulate other transcripts that produce proteins 
characteristic of mature fat cells. PPARy2 expression is limited to adipose 
tissue where it plays a central role in committing multipotential stem cells to 
the adipogenic lineage, as well as regulating differentiation of preadipocytes 
into adipocytes (Tontonoz et al, 1994).
3.1.2 COX pathway and its metabolites in adipogenesis.
There is evidence that the COX pathway might be involved in regulating body 
fat and adipogenesis (Shillabeer et al, 1998). Arachidonic acid metabolites of 
the lipoxygenase as well as the cyclooxygenase pathway may be involved in
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regulating preadipocyte differentiation. However, results from several studies 
are conflicting and therefore inconclusive (Wolf, 1996; Lu et al, 2004; Fain et 
al, 2001; Lepak and Serrero 1993). Many reports imply specific roles for 
prostanoids produced by the mature adipocytes in the maintenance of 
terminal differentiation through an autocrine/paracrine control mechanism. 
Some of them, such as PGJ2, serve as potent natural ligands for PPARy, an 
important adipocyte transcription factor (Debril et al, 2001; Miwa et al, 2004; 
Nosjean et al, 2002). In 3T3-L1s it has been shown that the expression of 
COX-2 was induced transiently in a biphasic manner upon the triggering of 
the differentiation and maturation phases while COX-1 was constitutive (Lu et 
al, 2004; Yan et al, 2003). It has also been confirmed that PGD2 is formed 
from arachidonic acid by the mature adipocytes, suggesting conversion into 
PGJ2 derivatives (Lu et al, 2004). Inhibition of either COX-1 or COX-2 has 
been shown to facilitate differentiation, suggesting that both COX inhibit 
differentiation (Yan et al, 2003; Peterson et al, 2003). However there are other 
data showing opposite effects. Nishimura et al. demonstrated COX-1 
inhibition suppressed adipogenesis, suggesting a role of constitutive COX-1 in 
the endogenous synthesis of PGs and their ability to promote adipogenesis 
(Nishimura et al, 2004).
3.2 Aims(s)
Having established the importance of the COX pathway in the regulation of 
secretion of adipose IL-6 in the preceding chapter, effects of inhibitors of 
these enzymes on adipogenesis were investigated.
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These studies were undertaken to examine the potential role of COX pathway 
in modulating adipogenesis and to dissect the relative contributions of the two 
isoenzymes in this process.
To evaluate the role of COX pathway in the adipogenic changes, the effects of 
aspirin as a nonselective COX inhibitor and SC-560 and NS-398 as selective 
inhibitors of COX1 and COX 2 were investigated.
As cells are committed to the adipogenic cycle early effects were investigated 
during the first 72h (3-day) or 120h (5-day) in the presence or absence of 
various COX inhibitors.
3.3 METHODS
3.3.1 Preadipocyte Cell Culture and adipocyte differentiation
3T3-L1 preadipocytes were grown on 75 cm2 tissue culture flasks with 10 ml 
of Dulbecco’s Modified Eagle Medium (DMEM) containing 1% 
penicillin/streptomycin plus 10% bovine calf serum (BCS), at 37°C and 10% 
CO2 . When cells were nearly confluent (approximately 85%) they were 
trypsinised and seeded for differentiation or expanded.
The cells were seeded onto 25 cm2 flasks or 6-well tissue culture plates at a 
density of 4x105 cells/4ml media/flask or 6x104 cells /1.5 ml media/well, and 
incubated at 37°C and 10% C02 DMEM/BCS. After 24h the media was 
replaced with fresh media, DMEM containing 1% penicillin/streptomycin and 
10% cosmic calf serum (CCS). At confluence, preadipocytes were treated for 
72 hours, at 37°C and 10% C02, with a differentiation induction media 
consisting of DMEM with 10% CCS supplemented with the glucocorticoid, 
dexamethasone (0.1 pM), the phosphodiesterase inhibitor, 
isobutylmethylxanthine (IBMX, 0.5 mM), insulin (5 pg/ml) and the
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thiazolidinedione BRL 49653 (rosiglitazone, 1 pM). Induction media caused 
growth arrest and entry into the adipogenic cell cycle, followed by expression 
of adipocyte genes and lipid accumulation. Following 72h of induction the 
dexamethasone, IBMX and BRL 49653 were withdrawn and the cells fed with 
fresh DMEM/CCS containing 1 pM insulin (4 ml/flask or 1.5 ml/well). Cells 
were maintained in this media, which was replaced every 48 hours, until more 
than 90% of them were lipid containing adipocytes.
3.3.2 Interventions
The following COX inhibitors were used in these experiments: Vioxx or NS- 
398, COX-2 selective inhibitor at concentrations of 0,0.01,0.1 and 1.0pM, 
piroxicam or SC-560, COX-1 selective inhibitors at 0,0.01,0.1 and 1.0mM or 
0,0.01,0.1 and 1.0pM respectively, aspirin, a non-selective COX inhibitor at 
0.2, 1.0, 2.0, 5.0 mM. NS-398 and SC-560 were obtained from Cayman, 
Chemical, Vioxx was obtained from Merk Sharp & Dohme and aspirin and 
piroxicam were obtained from Sigma, Chemical.
In two different sets of experiments, various doses of aspirin (0.2,1.0, 2.0, 5.0 
mM) were added from day 0 (day of differentiation) to day 3 in one group and 
from day 0 to until day 5 in the other. Media were removed and retained for 
assay, and the 25 cm2 flasks or 6-well plates were flash frozen in liquid 
nitrogen and stored at -80°C prior to RNA isolation.
3.3.3 Microscopic examination
The cells were examined by light microscopy (Nikon, Eclipse) when media 
was changed.
A subset of cells were differentiated, on cover slips, in the absence or 
presence of aspirin, and used to assess lipid accumulation by confocal
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microscopy. Cells were loaded with 40 pM Bodipy 493/503, a neutral lipid dye, 
in HEPES buffer pH 7.4, for 15 minutes and viewed with a Zeiss confocal 
microscope. Images were processed using LSM 5 Image Processor.
3.3.4 RNA isolation and cDNA synthesis
RNA was isolated from cultured adipocytes as it was described in chapter 2 
(page 58).
Differentiated adipocytes were digested in 1 ml TRI-reagent (Sigma) and 
homogenised by pipetting. Total RNA was isolated in chloroform, precipitated 
overnight at 4°C in isopropyl alcohol, quantified by OD260/280 and visualised on 
a 1 % agarose gel containing 5% formaldehyde in MOPS buffer. 
cDNA was synthesized from the RNA samples by mixing 0.5pg of the isolated 
RNA, 7 pi 5x reverse transcriptase buffer, 3.5 pi 0.1 M DTT, 2 pi 20 mM dNTP, 
1 pi 40 U/pl RNAse inhibitor and 0.5 pi 50 pmol random oligonucleotide 
primers and Rnase free water up to a total volume of 33pl (Promega, 
Southampton, UK).
3.3.5 Taq-man Real-time PCR Analysis
Taq-man Real-time PCR was performed as it has been explained in chapter 2 
in details (page 59).
25 pi total volume of samples (consisted of 1.25 pi specific primer, 12.5 pi 
SYBR-Green solution, 1 pi cDNA and 10.25 pi nuclease-free water) per well 
was run in duplicate. A negative control for each primer was included in PCR 
reaction. GAPDH as a control mRNA was also run in duplicate.
Data were obtained from a minimum of at least six separate experiments. 
GAPDH, PPARy, C/EBPa, and adipsin were used in this set of experiments.
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3.4 RESULTS
3.4.1 Morphological examination by light microscopy
In control cells, after 72 hours of induction of differentiation most of the cells 
(>90%) had changed from spindle shaped fibroblast-like preadipocytes to the 
. rounded morphology of the adipocyte. In this batch of cells, at days 5 to 7 
after induction of differentiation, the majority of cells were differentiated and 
grown in volume until more than 90% of the cell was lipid.
Changes from preadipocyte to adipocyte transformation were less 
pronounced when using different concentrations of aspirin in a dose 
dependent manner. Microscopically, there was no difference between 
adipocyte controls (Cellgro) and those treated with 0.2mM aspirin. However, 1 
and 2mM aspirin significantly reduced the number of adipocyte-like cells. At 
the highest dose of aspirin (5mM) none of the cells adopted an adipocyte-like 
morphology or accumulate lipid.
There was no difference between adipocyte controls and those treated with 
lower doses of Vioxx (0.01 and 0.1 pM). However aspirin (1.0 or 2.0 mM), 
piroxicam (1mM) and SC-560 (0.01, 0.1 and 1.0 pM) reduced the number of 
adipocyte-like cells. Similarly, in these groups of cells there was reduced lipid 
content (with light microscope).
Conversely intervention with higher doses of Vioxx (1pM) resulted in larger 
lipid droplets within the cell when compared with untreated cells.
Confocal microscopy with the neutral lipid dye BODIPY 493/503 confirmed the 
observation that aspirin decreases the lipid content of adipocytes during 
differentiation.
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3.4.2 Real time Taq-man PCR
To determine a mechanism for the effect of aspirin on adipogenesis, RT-PCR 
was used. Adipsin expression was investigated as an adipocyte marker that 
increased throughout adipogenesis.
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Figure 3.1: Adipsin mRNA expression in 3T3.L1 adipocytes from DO (day 
of differentiation) to D5 (day 5)
Increased expression of adipsin, an early adipogenic marker, has been shown 
after five days post-induction.
After 5 days of induction and differentiation the aspirin treated cells had 
significantly lower expression of adipsin compared to those differentiated 
without aspirin. The inhibition was more significant with higher doses of 
aspirin (5mM) (Figure 3.2). Decrease in adipsin expression in aspirin treated 
cells confirms our microscopic examinations. Piroxicam as a selective COX 1 
inhibitor appears to have no effect on adipsin expression at lower
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concentrations (0.01 and 0.1 mM), but 1mM of piroxicam significantly reduced 
adipsin expression.
Adipsin expression was increased in response to NS-398 as a selective COX 
2 inhibitor (0.1 pM and 1 .OpM), although the rise was not statistically significant 
at the lower concentration (0.01 pM).
Control Aspirin Piroxicam Vioxx
Figure 3.2: Effect of chronic exposure of COX inhibitors on adipsin 
mRNA expression in 3T3L1 from DO to D5.
Significant reduction in adipsin mRNA expression has been seen in aspirin 
treated cells and also with higher concentration (1mM) of selective COX-1 
inhibitor, piroxicam. Vioxx, a selective COX-2 inhibitor, had no effect or even 
positive effect on adipsin expression.
Aspirin (black: 0.2mM; white: 1.0mM; grey: 5.0mM), Piroxicam (black: 
0.01 mM; white: 0.1 mM; grey: 1.0mM), Vioxx: (black: 0.01 pM; white: 0.1 pM; 
grey: 1.0pM)
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To investigate a possible mechanism of aspirin on adipocyte differentiation, 
the expression of a number of adipocyte differentiation-related genes were 
examined. PPARy and C/EBPa are essential for adipocyte differentiation. 
Expression of both is maintained at a low level in preadipocytes, but is quickly 
up-regulated following induction of differentiation. Increasing PPARy and 
C/EBPa expression in control cells was demonstrated from the preadipocyte 
state to 5 days post-induction in (Fig 3.3 and 3.4)
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Figure 3.3: PPARy expression in 3T3.L1 adipocytes from DO (day of 
differentiation) to D5 (day 5)
Increased mRNA expression of PPARy a major adipogenic transcription factor 
has been shown immediately following induction of adipocyte differentiation 
and after five days post-induction
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Figure 3.4: CEBPa expression in 3T3.L1 adipocytes from DO (day of 
differentiation) to D5 (day 5)
Increased mRNA expression of CEBPa, an adipogenic transcription factor 
that along with PPARy, facilitates adipogenesis, is apparent early in the 
induction of differentiation and after five days post-induction
In the cells receiving intervention with aspirin (>0.2mM) and Piroxicam (1mM) 
there was also inhibition of adipocyte transcription factors, PPARy and 
C/EBPa, especially after exposure for 5 days.
Investigation of these two major differentiation factors shows dose-dependent 
down-regulation of both genes in aspirin treated cells. The trend of down- 
regulation of PPARy gene in aspirin treated cells was nearly identical on day 3 
and 5. However, when using 5 mM the effect was distinctly greater after 5 
days.
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Figure 3.5: Effect of aspirin on PPARy expression during adipogenesis 
of 3T3.L1 preadipocytes Figure shows significant dose-dependent inhibition 
of PPARy expression as an adipocyte transcription factor at the mRNA level 
after treatment with aspirin for 3 days. (Con, Control; AspO.2, Aspirin 0.2mM; 
Asp1, Aspirin 1mM; Asp2, Aspirin 2mM; Asp5, Aspirin 5mM)
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Figure 3.6: Effect of aspirin on PPARy expression in 3T3.L1 from the 
preadipocyte state to 5 days post-induction
Figure shows significant inhibition of PPARy expression as an adipocyte 
transcription factor at mRNA level after treatment with aspirin for 5 days. 
(ConD5, Control day 5; AspO.2, Aspirin 0.2mM; Asp1, Aspirin 1mM; Asp2, 
Aspirin 2mM; Asp5, Aspirin 5mM)
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Comparison of the expression of C/EBPa, in cells treated with or without 
different concentrations of aspirin during differentiation, indicated down- 
regulation in a dose-dependent manner after 72 hours. The trend of inhibition 
was the same after 5 days despite a non-significant increase in C/EBPa 
expression with 1 and 2 mM aspirin compared to 0.2 mM. But obviously, 
C/EBPa expression was affected with higher concentration of aspirin (5mM) 
during differentiation as well as 5 days post-induction.
In conclusion, the primary observation, (inhibition of differentiation), was 
confirmed using adipsin as a marker of adipocyte differentiation and 
transcription factors as markers of adipogenesis.
Aspirin suppressed adipogenesis in a dose-dependent manner. Higher 
concentrations of SC-560 and piroxicam, (as specific COX-1 inhibitors), also 
suppressed adipogenesis. NS-398, a selective COX-2 inhibitor, however, 
induced adipogenesis, and dose-dependently increased cellular lipid 
accumulation and induced greater number of preadipocyte to adipocyte 
conversion.
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Figure 3.7: Effect of aspirin on CEBPa expression in 3T3.L1 from the 
preadipocyte state to 3 days post-induction Figure shows significant 
inhibition of CEBPa expression as an adipocyte transcription factor at mRNA 
level after treatment with aspirin for 3 days. (Con, Control; AspO.2, Aspirin 
0.2mM; Asp1, Aspirin 1mM; Asp2, Aspirin 2mM; Asp5, Aspirin 5mM)
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Figure 3.8: Effect of aspirin on CEBPa in 3T3.L1 from the preadipocyte 
state to 5 days post-induction Figure shows significant inhibition of CEBPa 
expression as an adipocyte transcription factor at mRNA level after treatment 
with aspirin for 5 days. (ConD5, Control day 5; AspO.2, Aspirin 0.2mM; Asp1, 
Aspirin 1mM; Asp2, Aspirin 2mM; Asp5, Aspirin 5mM)
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3.5 DISCUSSION
It is well accepted that there are two isoforms of cyclooxygenases, COX-1 
and COX-2. COX-1 is expressed constitutively in most tissues and appears to 
be responsible for various physiological functions. COX-2, which is a key 
enzyme in prostaglandin synthesis, is an immediate-early response gene that 
is rapidly induced by many factors such as growth factors and cytokines.
To investigate a possible mechanism of aspirin on adipocyte differentiation, 
morphological changes, as well as alterations in the expression of a number 
of adipocyte specific- and differentiation-related genes were examined. 
Central to the mechanism of adipocyte differentiation are the transcription 
factors C/EBPa and P P A R y  (Brun et al, 1997; Rosen, 2002), which control the 
expression of numerous genes required for adipose conversion and function, 
and are essential for adipose conversion to occur. Over-expression of either 
P P A R y (Tontonoz et al, 1994) or C/EBPa (Freytag et al, 1994; Wu et al, 1995) 
leads to differentiation. Alternatively, incubation of preadipocytes with a 
P P A R y ligand, such as the thiazolidinediones, is sufficient to cause adipocyte 
differentiation (De Vos, 1996; Mizukami et al, 1997).
Chronic exposure of differentiating adipocytes to aspirin inhibited the 
expression of adipogenic transcription factor P P A R y. Aspirin also inhibited 
C/EBPa, the second main transcription factor of adipocyte differentiation. 
These reductions would negatively affect differentiation and therefore 
adipogenesis. The down-stream effect of P P A R y inhibition would be the 
abrogation of various PPAR-regulated genes. Among them are the genes that 
are required for adipogenesis and also the ones that are important in the 
function of mature adipocytes. Aspirin reduced adipsin expression, as a
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marker of adipocyte differentiation. The reduction could be the consequence 
of PPARy and C/EBPa inhibition. This observation confirmed data, obtained 
from microscopic evaluation, of maintenance of pre-adipocyte-like 
morphology.
Aspirin suppressed adipogenesis in a dose-dependent manner. Higher 
concentrations of SC-560 (0.1 and 1 pM) and piroxicam (1mM) as specific 
COX-1 inhibitors, also suppressed adipogenesis. NS-398, a selective COX-2 
inhibitor, not only had negative influence on the maturation processes, but 
also increased fat lipid droplets and mature adipocytes dose-dependently. 
Previous data showed that (chapter 2), aspirin as a non selective COX 
inhibitor and Vioxx as a selective COX-2 inhibitor decrease IL-6 release from 
adipocytes. In spite of some data that showed IL-6 could induce PPARy 
activation and therefore adipogenesis, it is unlikely that the effect of these 
COX inhibitors on adipogenesis could be through inhibition of IL-6 release. 
First of all, the direct mechanism of IL-6 on differentiation has yet to be 
elucidated and according to the data in our group it has an effect on lipid 
engorgement compared to adipogenesis. Secondly, as it has already been 
shown, both aspirin and Vioxx have inhibitory effects on IL-6 release, but in 
terms of adipogenesis they behave differently. Another important factor which 
should be considered is the role of prostaglandin in differentiation. 
Prostaglandins are major regulators of cell growth, differentiation, and 
homeostasis. They are m,ade through the action of COX pathway. 
Cyclooxygenase (COX) catalyzes the rate-limiting step of prostanoid 
biosynthesis and controls the first committed step of prostanoid formation. The 
availability of this enzyme directly relates to the abundance of prostaglandin
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production. But the patterns of COX-1 and COX-2 expressions are distinctly 
different. They might therefore play different roles in adipose cell biology. The 
divergent function of these two isoforms may be attributable to the availability 
of the enzyme under particular settings or the functional coupling with different 
downstream terminal PG synthases.
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CHAPTER 4: ADMA/DDAH AXIS IN ADIPOSE TISSUE
4.1 INTRODUCTION
Obesity is closely associated with the development of type 2 diabetes and 
cardiovascular disease (Pi-Sunyer et al, 2002; Caballero et al, 2003). Both 
insulin sensitivity and endothelial nitric oxide (NO) bioavailability are 
modulated by adiposity and altered NO levels may explain the insulin 
resistance and endothelial dysfunction of obesity (Ziccardi et al, 2002; Hamdy 
et al, 2003). Although it has been postulated that adipose tissue-derived 
mediators act on the endothelium to produce detrimental effects, none has 
clearly been identified (Mohamed-Ali et al, 1998; Bergman et al, 1998). 
Recently, elevated plasma concentration of the naturally occurring NO 
synthase inhibitor, asymmetric dimethylarginine (ADMA), has been identified 
as a risk factor for type 2 diabetes and cardiovascular disease (Vallance et al, 
1992; Boger et al, 2003) and the circulating concentration of ADMA correlates 
closely with the degree of insulin resistance (Stuhlinger et al, 2002). ADMA 
and the inert isomer symmetric dimthethylarginine (SDMA) are released 
during the hydrolysis of proteins that contain arginine residues methylated by 
protein arginine methyltransferases (PRMTs) (Clarke, 1993). The primary 
route of catabolism of ADMA is by the enzyme DDAH to form citrulline and 
dimethlyamine (Leiper and Vallance 2003). In contrast, SDMA is excreted 
unchanged in the urine. Two isoforms of DDAH have been identified and 
expression reported in several tissues (Leiper et al, 1999).
4.2 AIMS(s)
Given the role of DDAH in the regulation of ADMA degradation, it was 
postulated that adipose tissue is a source of ADMA in obesity and
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interventions that alter adipose DDAH expression would be expected to 
modulate ADMA levels.
4.3 METHODS
4.3.1 Mouse studies.
DDAH1+/' mice on a mixed agouti C57BI/6 background were generated. 
Genotyping of mice was performed by Southern blot analysis. C57BL/6 and 
ob'A (Harlan, UK) male, 12 week old mice were bled by cardiac puncture and 
then killed by cervical dislocation prior to removal of the dorsal lumbar sub­
cutaneous and the epididymal adipose tissue depots.
4.3.2 Human studies.
All subjects taking part gave informed written consent to these studies, which 
had previously been approved by the local ethics committee.
4.3.2.1 Arterio-venous difference study.
This part of study was in collaboration with Oxford Centre for Diabetes, 
(endocrinology and metabolism department) at university of Oxford. Arterio­
venous differences were measured in 12 healthy Caucasian male volunteers 
(BMI 26.6{24.2-36.7kg.m'2}) studied after an overnight fast. Cannulae were 
inserted into the superficial epigastric vein draining the subcutaneous 
abdominal adipose tissue (Frayn et al, 1989), into a deep antecubital vein, 
draining the deep forearm tissue and, to a vein on the back of hand to provide 
arterialised venous blood by heating the hand in a hot box at +60 C. All lines 
were kept patent by a slow infusion of saline. Blood samples were taken 
simultaneously from the different sites. Previous work has shown that venous 
blood from the superficial epigastric veins approximates the effluent from an
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adipose tissue bed, and arterio-venous differences across abdominal tissue 
yields results in good agreement with those of microdialysis studies. Deep 
antecubital vein samples approximate the venous effluent of the skeletal 
muscle (Frayn et al, 1993).
4.3.2.2 Weight loss study.
This part of study was in collaboration with Franz Volhard Clinic, Medical 
Faculty of the Charite at Humboldt University of Berlin and Max Delbruck 
Centre for Molecular Medicine.
Fifteen, healthy, post-menopausal, Caucasian women participated in this 
study. All medication was stopped at least 7 days and hormone replacement 
at least four weeks before the study. The women were weight stable to 1kg 
during three months preceding the study. Baseline blood samples and an 
adipose tissue biopsy were obtained in the morning after an overnight fast.
Weight reduction was achieved by dietary counselling (reduction of energy 
intake by 600 kcal/day). Repeat blood samples, adipose tissue biopsies and 
clinical measurements were taken after 5% weight loss was achieved.
4.3.2.3 Adipose tissue biopsy.
Abdominal sub-cutaneous adipose tissue samples (1.5-3.0g) were obtained 
by needle biopsy under local anaesthesia from the periumbilical region.
4.3.2.4 Organ culture of adipose tissue.
Subcutaneous and epididymal adipose tissue was removed from C57BL/6, 
ob'/_ and DDAH1+/" mice. The tissue was removed and prepared for 
experiment as it has been described in chapter 2 (page 55).
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0.2g of adipose tissue from both depots was incubated in serum-free media 
(Cellgro, Hyclone, USA) for 24h at 37°C / 5% CO2 in the absence of any 
additives. At the end of the incubation, media was removed and retained for 
ADMA assay and the tissue was snap frozen in liquid N2 and stored at -80°C 
for RNA and protein extraction. In intervention study, 0.2g of fat tissue from 
both depots was placed in 6-well plates. Tissue fragments were incubated in 
Cellgro containing rosiglitasone (20pM), TNFa (20ng/ml), IL-6 (10 ng/ml), 
PGJ2 (20 pM) and aspirin (0.2, 1 and 2 mM). After 24 hours of incubation, the 
tissue was frozen in liquid N2 and stored at -80°C along with the culture 
supernatant. Serum-free media was used as a basal control.
4.3.3 Assays.
Insulin concentrations were determined by radio-immunoassay (DPC 
Biermann, Germany) and glucose by polarography (Beckmann, Germany). 
Insulin resistance was calculated from fasting plasma insulin and glucose 
concentrations by homeostasis model assessment (HOMA). DDAH activity 
was assessed using a radiochemical assay for the metabolism of 14C-labelled 
L-NMMA with a few modifications of a previously reported method 
(MacAllister et al, 1996). Briefly, 50pl of adipose tissue lysate was incubated 
at 37°C for 90 minutes with 50pl of phosphate buffered saline, containing 
0.02mCi of L-[14C]-NMMA and 20pM unlabelled L-NMMA. Following 
incubation [14C]-citrulline was measured by mixing with 1ml of 50% (w/v) 
Dowex 50X8-400 and centrifuging for 3 minutes at 13,000rpm. 100pl of the 
supernatant was mixed with 5ml of scintillation fluid and the 14C content 
measured.
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4.3.3.1 ADMA Extraction
ADMA measured by HPLC with fluorescence detection. 0.2 ml of plasma was 
mixed with 40pl of a 10ng//vl solution of the internal standard M N- 
monomethyl-L-arginine (L-NMMA) and 0.760 ml of PBS. In cell culture (or 
organ culture), 10pl L-Homoarginine (10 mg/L) was added to certain amount 
of supernatant (0.5 ml) as an internal standard.
This mixture was applied to Oasis MCX solid-phase extraction columns 
(Waters). The columns were washed consecutively with 1.0 ml of 0.1 mol/l 
HCI and 1.0 ml of methanol. Basic amino acids were eluted with 1.0 ml of 
concentration ammonia/water/methanol (10:40:50, by volume). After 
evaporation of the solvent under nitrogen, the amino acids were derivatized 
with o-phthaldialdehyde reagent containing 3-mercaptopropionic acid. The 
derivatives were separated by isocratic reverse-phase chromatography on a 
Symmetry C18 column (3.9 mm* 150 mm; 5 pm particle size; Waters) at a 
column temperature of 30°C. Potassium phosphate buffer (50 mmol/pH 6.5), 
containing 8.7% acetonitrile, was used as mobile phase at a flow rate of 1.1 
ml/min. After elution of the last analyte, strongly retained compounds were 
quickly eluted by a strong solvent flush with acetonitrile. Fluorescence 
detection was performed at excitation and emission wavelengths of 340 and 
455 nm respectively. All samples from individual patients, cell or tissue 
supernatant were analyzed in the same analytical series.
4.3.4 Western blot analysis
Western blot analysis has been done as it has been described in chapter 2 
(page 57). Protein was isolated from approximately 200mg of the adipose 
tissue. The tissue was crushed and lysed in protein lysis buffer (1x PBS,
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containing 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) supplemented 
with protease inhibitors (Complete, Boehringer Mannhein, UK). The 
homogenate was centrifuged at 14,000rpm for 15 minutes and the infranatent 
recovered. The protein content was estimated with a kit from Biorad, UK. 
Twenty microgram of total protein was loaded onto gels and separated by 
SDS-PAGE electrophoresis. Gels were blotted onto PVDF membranes and 
blocked with 5% non-fat dried milk and probed with monoclonal antibodies 
against DDAH 1 and 2 that were raised to peptides used previously to 
generate polyclonal antibodies to these molecules. Secondary antibodies 
conjugated to horse-radish peroxidase were from Amersham Bioscience. 
Antigen-antibody complexes were detected by chemiluminescence with an 
ECL kit (Amersham) and blots exposed to high performance 
chemiluminescence film (Kodak).
4.3.5 RNA extraction and real-time PCR.
Total RNA was isolated from adipose tissue with an RNeasy lipid tissue mini­
kit (Qiagen). Two microgram of RNA was reverse-transcribed to cDNA with 
the use of random hexamers (Retroscipt, Ambion, Inc.). Real-time PCR was 
performed with an ABI 5700 sequence detection system. Primers and probe 
sequences for mouse DDAH 1 and DDAH 2 were selected with Primer 
Express (Perkin-Elmer Applied Biosystems). Primer-probe sets for human 
DDAH1 and 2 (Assays-on-Demand) were from Applied Biosystems. Each 
gene assay was run in a singleplex reaction in duplicate with Taqman 
universal PCR master mix (Applied Biosystems); PCR reactions (25pl) 
contained 3pl of 1:100 diluted cDNA. GAPDH expression levels were used to 
normalize gene expression in each sample.
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4.3.6 Statistical analysis.
Results are expressed as mean±SD or median (interquartile range). 
Comparisons between two groups were made by paired or unpaired two- 
tailed Student's t-test, Mann-Whitney U test or Wilcoxon rank test, as 
appropriate. P< 0.05 was considered to be statistically significant.
4.4 RESULTS
4.4.1 Protein expression
Expression of both DDAH isoforms was investigated in a murine preadipocyte 
cell-line, 3T3-L1, using western blot. Both undifferentiated and differentiated 
adipocytes expressed DDAH 1 and 2, however adipocytes expressed less 
DDAH 1 and 2 compared to the preadipocytes.
DDAH1 and 2 proteins were also investigated in sub-cutaneous and 
epididymal adipose tissue. Significant expression and activity was found at 
levels comparable to those seen in tissues such as kidney and liver (Fig 4.1). 
Figure 4.1: DDAH protein expression in different tissues
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On comparing the level of DDAH protein expression in adipose tissue from 
ob/ob mice, as a genetic model of obesity, compared to lean C57BL/6 
controls, lower levels of protein expression were observed in subcutaneous 
adipose tissue in obese mouse (Fig 4.2).
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Figure 4.2: DDAH expression in subcutaneous murine adipose tissue 
(C57BL/6 and ob/ob)
4.4.2 mRNA expression
At the mRNA level, both preadipocytes and differentiated adipocytes 
expressed DDAH 1 and 2 that was confirmed by using Taq-man real time 
PCR. However, the expression of DDAH 1 and 2 was less in adipocytes than 
preadipocytes (Fig 4.3).
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Figure 4.3: mRNA expression of DDAH 1 and 2 in preadipocytes and 
adipocytes by Taq-man real time PCR
DDAH mRNA expression was investigated in subcutaneous and epididymal 
adipose tissue from C57BL/6 and ob/ob animals. It was shown that ob/ob 
animals expressed less DDAH 1 and 2 compared to C57BL/6 controls (Fig 
4.4).
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Figure 4.4: mRNA expression of 
DDAH 1 and 2 in murine adipose 
tissue (C57BL/6 versus ob/ob) by 
Taq-man real time PCR
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In human adipose tissue, both DDAH 1 and 2 were expressed at mRNA level. 
The expression of these enzymes was compared from biopsy specimens from 
lean and obese individuals. Sub-cutaneous adipose tissue mRNA expression 
of DDAH 1 and 2 were lower in obese subjects compared to lean individuals 
(Table 4.1).
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Variable Lean Obese
number 18 18
age [years] 56 ±4 58 ±5
BMI [kg/m2] 23.9 ±2.1 35.7 ±4.1 *
waist circumference [cm] 79 ±7 105 ± 10*
glucose [mmol/l] 4.9 ± 0.5 5.4 ± 0.4 *
insulin [pU/l] 2.9+ 1.5 6.9 ± 3.5 *
HOMA index 0.7 ± 0.4 1.7 ±0.9*
DDAH1/GAPDH [arbitrary 
units]
1.64
(1.15-2.00)
0.89*
(0.73-1.54)
DDAH2/GAPDH [arbitrary 
units]
5.94
(4.32-8.49)
4.71
(3.32-8.44)
ADMA (pM)
0.55
(0.52-0.58)
0.56
(0.49-0.63)
Table 4.1: Effect of obesity on adipose tissue DDAH expression and 
circulating ADMA *: p<0.01
Interestingly, with the reduction in body weight there was a median increase 
in adipose tissue mRNA expression levels of DDAH 1 (43% increase) and 
DDAH 2 (24% increase) (Table 4.2).
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mRNA
(arbitrary units)
Before After
DDAH1/GAPDH 0.86
(0.64-1.21)
1.23*
(0.87-2.08)
DDAH2/GAPDH 4.20
(2.91-7.49)
5.22*
(3.50-9.07)
Table 4.2: Taq-m an real time PCR analysis o f DDAH 1 and DDAH 2 
expression before and after w eight loss. *: p<0.01
4.4.3 ADMA level
Both undifferentiated and differentiated adipocytes released detectable ADMA 
levels into the culture media. However, the differentiated adipocytes released 
significantly more ADMA, compared to the preadipocytes (Fig 4.5).
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Figure 4.5: ADM A release from preadipocytes and adipocytes
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In organ cultures of adipose tissue, the level of ADMA in the culture media 
was increased with increasing fat mass. There was also higher release of 
ADMA from subcutaneous fat compared to epididymal tissue (Fig 4.6). The 
level of adipose ADMA release from DDAH1+/‘ mice was also investigated. 
The release of ADMA from heterozygous explant tissue was 2.1 fold more 
than release of ADMA from wild-type control animals (Fig 4.6).
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Figure 4.6: ADMA release from adipose tissue explants
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ob/ob animals were used as a genetic model of murine obesity with insulin- 
resistance. The levels of ADMA in circulation were higher in ob/ob animals 
compared to lean C57BL/6 control animals (p=0.03). The release of ADMA 
from ob/ob explant adipose tissue was also significant higher than the release 
from the same amount of tissue in lean animals (Fig 4.7).
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Figure 4.7: Effect of obesity on ADMA release in murine adipose tissue.
sc, sub-cutaneous adipose tissue; epid, epididymal adipose tissue, Data 
C57BL/6, n=8; ob'^, n=5. All data shown as mean ±SD.
In the human study, systemic ADMA concentrations were measured in lean 
and obese age-matched women. The obese subjects were hyperglycaemic 
and more insulin resistant compared to the lean volunteers and had
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significantly higher levels of DDAH 1 mRNA expression in their adipose tissue 
(Table 4.1). While the trend for DDAH2 expression in the lean tissue was also 
higher it did not reach significance and circulating levels of ADMA was also 
not different between lean and obese subjects.
In the study of subjects who achieved a median weight loss of 5.2%, plasma 
ADMA levels after weight loss we re significantly lower compared to the their 
levels before weight loss (Fig 4.8).
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Figure 4.8: Effect of weight loss on systemic ADMA levels
Weight loss was accompanied by a significant reduction in BMI, waist 
circumference and HOMA index of insulin resistance. However, there was no 
change in plasma lipids or glucose (Table 4.3).
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Variable Baseline After weight loss
BMI [kg/m2] 33.1 ±4.6 31.2 ±4 .3 *
waist circumference [cm] 101 ±11 97 ± 11 *
total cholesterol [mmol/I] 5.7 ±1.0 5.5 ±1.1
HDL-cholesterol [mmol/l] 1.7 ±0.4 1.6 ±0.4
LDL-cholesterol [mmol/l] 3.5 ±0.9 3.3 ±1.0
triglycerides [mmol/l] 1.2 ±0.5 1.3 ±0.6
glucose [mmol/l] 5.7 ±0.8 5.7 ±0.8
insulin QiU/i] 4.8 ±3.3 3.9 ±2.5*
HOMA index 1.2 ±0.9 1.0 ± 0.7 *
Table 4.3: Effect of weight loss on glucose and lipid profiles *p<0.01 
Arterio-venous differences were measured across a human abdominal sub­
cutaneous adipose tissue bed and forearm muscle. ADMA levels were 
significantly elevated in the epigastric vein compared to that from the radial 
artery (Fig 4.9a). SDMA levels were not significantly different between the 
different sites of sampling (Fig 4.9b). Furthermore, no significant difference 
was detectable for ADMA across the forearm muscle in these subjects (Fig 
4.9c).
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4.4.4 Result (Intervention study)
After 24 hours treatment of adipose tissue explants with 20pM rosiglitazone, 
DDAH1 expression was increased at both mRNA and protein levels (Fig 
4.10a,b). There was also an increase in DDAH 2 expression, but not as much 
as DDAH1.
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Figure 4.10: Effect of Rosiglitazone on mouse adipose tissue DDAH 
expression and ADMA release.
112
Treatment of adipose tissue explants with TNFa also increased DDAH1 
protein expression, but there was not significant change in DDAH expression 
in IL-6 and PG J2 treated tissues. The effect of aspirin on DDAH expression 
was different in subcutaneous and visceral adipose tissue. In other words, 
they behave differently in these depots of adipose tissue, which needs more 
work and exploration (data has not been shown).
ADMA release by tissue was reduced in TZD treated explants compared to 
control tissues (Fig 4.10c).
TNFa (20 ng/ml) also reduced ADMA release from the subcutaneous and 
epididymal adipose tissue. But exposure of tissue fragments with IL-6 (10ng) 
and PGJ2 (20 pM) did not affect ADMA release compared to control (Fig 
4.11 a,b). Change in the release of ADMA in aspirin treated explants 
compared to basal was variable, but there was a trend of reduction of ADMA 
levels in subcutaneous explants compared to basal release.
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Figure 4.11a: Effect of TNFa, IL-6 and PGJ2 on ADMA release from sub 
cutaneous mouse adipose tissue.
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Figure 4.11b: Effect of TNFa, IL-6 and PGJ2 on ADMA release from 
epididymal mouse adipose tissue.
TNFa (Tumor Necrosis Factor alpha: 20 ng/ml), IL-6 (Interleukin 6: 10ng) and 
PGJ2 (Prostaglandin J2: 20 pM); data shown as mean ±SD, n=6.
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4.5 DISCUSSION
Expression of both DDAH isoforms was established in a murine preadipocyte 
cell-line, 3T3-L1. Both undifferentiated and differentiated adipocytes 
expressed DDAH 1 and 2 mRNA and released ADMA into the culture media. 
However, the differentiated adipocytes expressed less DDAH 1 and 2, and 
released significantly more ADMA, compared to the preadipocytes. DDAH1 
and 2 proteins were investigated in subcutaneous and epididymal adipose 
tissue. Significant expression of these proteins was found at the levels 
comparable to those seen in kidney and liver (Fig 4.1). In organ cultures of 
adipose tissue, ADMA accumulation in the culture media was proportional to 
the mass of the tissue explants and the release of ADMA from subcutaneous 
fat was significantly higher than that observed from epididymal tissue (Fig 
4.6). Degradation of ADMA is catalysed by DDAH and so changes in the 
expression of the enzyme would be expected to alter the extent of ADMA 
degradation by the tissue. Therefore adipose ADMA release from tissue 
obtained from DDAH1+/' mice was assessed. The explant tissue from the 
heterozygous mice released 2.1 fold more ADMA compared to that seen in 
tissue from wild-type control animals (Fig 4.6), confirming the essential role of 
DDAH in regulating ADMA levels within tissues.
Endothelial function is impaired in leptin-deficient ob'7' mice and this may be 
an excellent model for the study of the cardiovascular effects of obesity 
(Winters et al, 2000). These animals also exhibit many features of non-insulin- 
dependent diabetes such as mild hyperglycaemia, hyperlipidemia, and 
hyperinsulinemia. These insulin-resistant mice were used as a genetic model 
of murine obesity and found that systemic ADMA levels were higher in these
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animals compared to lean C57BL/6 control animals (p=0.03). Furthermore, 
adipose tissue obtained from ob'A mice expressed lower levels of DDAH 1 and 
2, and released significantly more ADMA, compared to tissue obtained from 
lean animals (Fig. 4.2; 4.4; and 4.7). Thus lower overall DDAH activity in the 
adipose tissue of ob'A animals probably accounts for the elevated ADMA 
secretion.
To determine whether the results observed in rodents are valid in humans, 
and to test the hypothesis that the adipose tissue is a significant source of 
ADMA in vivo arterio-venous differences across a human abdominal sub­
cutaneous adipose tissue bed and forearm muscle were measured (Frayn et 
al, 1989). It was found significant elevation in ADMA levels in the epigastric 
vein sample compared to that in arterialized blood from a vein on the back of 
hand, confirming release of ADMA from this adipose depot (Fig 4.9a). SDMA 
levels were not significantly different between the different sites of sampling 
(Fig 4.9b). Furthermore, no significant difference was detectable for ADMA 
between the forearm deep vein and arterialized venous blood, suggesting that 
skeletal muscle is not a significant source of ADMA (Fig 4.9c).
Weight loss and the reduction in adipose tissue have been shown to improve 
insulin resistance and endothelial dysfunction (Ziccardi et al, 2002; Hamdy et 
al, 2003; Raitakari et al, 2004). In this study, women achieved a median 
weight loss of 5.2% (range 4.3 to 9.7 %) over 13 weeks (range 11 to 18 
weeks) by caloric restriction. In these subjects weight loss was accompanied 
by a significant reduction in BMI, waist circumference and HOMA index of 
insulin resistance. However, there was no change in plasma lipids or glucose 
(Table 4.3). With the reduction in body weight there was a median increase in
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adipose tissue mRNA expression levels of DDAH 1 (43% increase) and 
DDAH 2 (24% increase) and plasma ADMA declined significantly (Table 4.2 
and Fig 4.8). Previous studies have shown that a 7-10% weight reduction 
improves flow-mediated vasodilatation in diabetic and non-diabetic obese 
individuals (Ziccardi et al, 2002; Hamdy et al, 2003; Caballero, 2004; Raitakari 
et al, 2004). These observations that a more modest weight loss that causes 
no discernable change in plasma glucose results in a fall in ADMA suggests 
that changes in adipose ADMA metabolism may precede detectable 
improvement in endothelial function in obesity.
Thiozolidinediones (TZDs) are potent insulin sensitizers that lower blood 
sugar (Seufert et al, 2004) but also appear to improve other abnormalities 
associated with type 2 diabetes, including hyperlipidemia, atherosclerosis, 
hypertension and chronic inflammation (Willson et al, 2001). They also 
ameliorate endothelial dysfunction (Dandona and Aljada 2004). In the present 
study treatment of adipose tissue explants with rosiglitazone (20pM), a TZD 
that has been shown to reduce systemic levels of ADMA (Stuhlinger et al, 
2002), increased the expression of DDAH1, and to a lesser extent DDAH2, at 
both the mRNA and protein levels (Fig 4.10a,b). Furthermore ADMA release 
by the tissue was reduced in TZD treated compared to control tissue (Fig 
4.10c). It has already been shown the presence of a PPARy consensus 
sequence in the promoter of the DDAH2 gene (Tran et al, 2000). This data 
also support a role for PPARy in the regulation of DDAH 1 expression.
Adipose tissue is partitioned into a few large depots, including the 
subcutaneous and visceral sites, and many small depots that lie in close 
proximity to a variety of organs such as muscle, nerves, blood vessels,
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connective and lymphoid tissue (Pond, 1999). Obesity is characterised by 
enlargement of many of the adipose tissue depots as well as infiltration of 
insulin responsive tissues such as skeletal muscle and liver with fat 
(Goodpaster et al, 2002). ADMA has been purported as a fundamental link 
between insulin resistance, endothelial dysfunction, lipid and glucose 
metabolism and cardiovascular disease (Stuhlinger et al, 2002; Cooke, 2000). 
These data has shown that adipose tissue is a significant source of ADMA, an 
endogenous inhibitor of all isoforms of NOS. The amount of ADMA generated 
is proportional to the mass of adipose tissue and inversely related to activity of 
DDAH within the tissue. The ADMA generated would affect NO-mediated 
functions of the adipose tissue itself, such as adipocyte growth and 
differentiation, local blood flow, glucose uptake and lipolysis, and inhibit NO 
mediated pathways in other insulin sensitive organs including systemic 
vascular endothelium, muscle and liver. Dietary and pharmacological 
interventions that improve insulin sensitivity and endothelial dysfunction 
increased adipose tissue expression of DDAH and reduced release of ADMA, 
suggesting that this may be a target for future therapies for obesity associated 
pathologies. The ADMA/DDAH pathway is a novel, modifiable adipose tissue 
regulatory mechanism for nitric oxide bioavailability.
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CHAPTER 5: DISCUSSION
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Obesity is the most prevalent nutritional disorder in industrialised countries 
and is a growing problem in the developing world (Kushner, 2002). Its 
consequential pathologies such as insulin resistance and endothelial 
dysfunction are closely associated with the development of coronary heart 
disease and type II diabetes (Yudkin et al, 1999). The exact role of, and 
mechanisms by which, increased obesity promotes cardiovascular disease is 
poorly understood, and the extent to which these diseases are reversible with 
weight loss is not yet clear. Factors derived from adipose tissue may causally 
underlie these relationships (Recasens et al, 2004)
Obesity is affected through increases in fat cell number, cell size and function. 
Obesity often leads to an increase in circulating cardiovascular risk factors, 
which may be involved in the development of cardiovascular disease 
(Levenson, 2002; Sorisky, 2002). Current evidence suggests that the 
association between obesity and cardiovascular disease can be explained, at 
least in part, by novel signalling molecules, adipokines, emanating from, or 
expressed in, adipose tissue. While the adipose tissue is the ultimate depot 
for the storage of energy in the form of triacylglycerol, adipocytes also play a 
dynamic role, influencing processes related to energy balance through the 
expression and secretion of molecules which regulate energy intake and 
expenditure by the organism (Spiegelman and Flier 2001).
Productions of most of the adipose tissue secreted factors are likely to be 
affected by obesity. Since obesity is associated with multiple metabolic 
disorders and increased risk of cardiovascular diseases, the idea has 
emerged that WAT could be instrumental in this complication, by virtue of its 
secreted factors. There is now compelling evidence that adipocytes act as
120
autocrine, endocrine and paracrine cells. A wide range of signals emanates 
from this tissue such as leptin, tumour necrosis factor-a (TNF-a), interleukin-6 
(IL-6), and their soluble receptors. These molecules are expressed in and 
released by adipocytes and their levels increase with increasing fat mass 
(Lyon et al, 2003). Signals derived from this tissue going to the brain (as a 
central effect) as well as peripheral tissue (liver, skeletal muscle, vasculature, 
and adipose tissue itself). For instance, Circulating IL-6 stimulates the 
hypothalamic-pituitary-adrenal (HPA) axis as well as its effect on liver and 
induction of hepatic acute phase response.
5.1 IL-6
IL-6 plays a key role in several mechanisms that contribute to the 
development of CHD (Yudkin et al, 2000). IL-6 is a powerful inducer of the 
hepatic acute phase response and several acute phase proteins, such as 
CRP and fibrinogen, are potent cardiovascular risk factors. Elevated 
concentrations of CRP are found in patients with acute coronary syndromes, 
and predict future risk in healthy subjects. Elevated levels of fibrinogen, with 
autocrine and paracrine activation of monocytes by IL-6 in the vessel wall 
contribute to the deposition of fibrin. The acute phase response is associated 
with increased blood viscosity, platelet number and activity. IL-6 decreases 
lipoprotein lipase (LPL) activity and LPL levels in plasma, which increases 
macrophage uptake of lipids (Yudkin et al, 2000).
Stimulation of hypothalamic-pituitary-adrenal (HPA) axis by IL-6 could be 
associated with central obesity, hypertension and insulin resistance. Thus IL-6 
is involved in the pathogenesis of CHD through a combination of autocrine, 
paracrine and endocrine mechanisms. IL-6 stimulates both thermogenesis
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and satiety, through a range of central effects, including prostaglandin 
synthesis and corticotrophin releasing hormone (CRH) release (Mastorakos et 
al, 1993).
Circulating IL-6 concentrations increase with age and obesity, both conditions 
often associated with increases in adipose tissue mass (Goodpaster, 2002).
5.1.1 Pathways of IL-6 secretion
The signalling pathways involved in adipocyte secretory and its metabolic 
functions, which lead to obesity and its associated pathologies, are poorly 
defined.
The expression and secretion of IL-6 appears to be regulated by several 
factors. A more complete understanding of the molecular and biochemical 
pathways regulating the biosynthesis of this molecule and its precise 
mechanism of action is likely to lead to new approaches for managing not only 
obesity but also cardiovascular disease.
Macrophages, endothelial cells, smooth and skeletal muscle and adipose 
tissue all produce interleukin-6 (IL-6), but differ in the regulation of this 
production. For example, skeletal muscle produces physiologically significant 
quantities of IL-6 in response to exercise. Both post-exercise and during 
infection the magnitude of the cytokine response is far greater but of a shorter 
duration, lasting hours to days. Obesity (excess adipose tissue), on the other 
hand, is associated with chronic low-level elevation of circulating IL-6, largely 
from adipose tissue. These levels have been shown to correlate with risk 
factors for type 2 diabetes and coronary heart disease. A proportion of 
adipose secretion of IL-6 is constitutive.
Systemic IL-6 is elevated in both murine and human obesity.
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Data from this work showed that basal IL-6 secretion in adipocytes and in 
adipose tissue was mediated through the COX-2 pathway metabolites, 
specifically PGE2 (chapter 2). It has been shown that in sub-cutaneous and 
intra-abdominal adipose tissue explants there was constitutive COX-2 
expression that increased over 48h incubation, (peak at 24h). Basal IL-6 
secretion mimicked the COX-2 expression and correlated with endogenous 
PGE2 production. Furthermore, COX inhibition significantly reduced IL-6 
production from adipose tissue, as well as IL-1p-induced IL-6 secretion in 
differentiated 3T3-L1 adipocytes.
Exogenous PGE2 and EP agonists induce IL-6 via EP4 receptors (present in 
AT- SV & macrophages) and elevation in intracellular cAMP, but independent 
of any changes in intracellular Ca2+. Understanding the specific pathway of 
adipose IL-6 release would allow targeted modulation of this function.
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Figure 5.1: Schematic pathway of IL-6 secretion in adipose tissue and 
adipocytes
Basal IL-6 secretion occurs through increased COX-2 mediated PGE2 release. Aspirin, 
a non-selective COX inhibitor, inhibits adipose IL-6 release. Prostaglandin E signals via 
EP receptors (EPs). EP-1 activation signals through a rise in intracellular [Ca2+], 
However, EP-2/4 receptors raise, and EP3 decreases intracellular cAMP. PGE2 
significantly stimulates IL-6 synthesis through both EP2 and EP4 receptors and 
elevated intracellular cAMP. Abbreviations: COX, Cyclooxygenase; EP, PGE2 receptor; 
IL-6, Interleukin 6; PG, Prostaglandin.
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5.1.2 IL-6 and adipogenesis
Since obesity is a condition with increased adipose tissue mass and 
accompanying chronic elevation in circulating levels of IL-6, the effect of IL-6 
as a growth factor for adipocytes and its consequence on adipogenesis was 
investigated.
The effect of IL-6 on adipocytes appears to be indirect, through increased 
secretion of leptin and lipid accumulation without any effect on the expression 
of the ob gene. However, adipogenesis was dose dependency inhibited by the 
non-selective COX inhibitor, aspirin (chapter 3). This effect of aspirin on 
adipocyte differentiation was mediated through the COX pathway. Since IL-6 
had no effect on adipogensis, the inhibitory effect of aspirin in treated 
adipocytes was independent of IL-6 levels. The effect of aspirin on 
adipogenesis was mediated through inhibition of transcription factors (PPARy 
and CEBPa). Using selective COX inhibitors it was found that the adipogenic 
effect is mediated through COX-1, which is different from the regulation of 
secretion, which appears to be a COX-2 mediated effect. There is not enough 
in vivo evidence to support the effect of aspirin on weight reduction. Almost all 
data in the literature reflect the effect of aspirin on weight loss in subjects with 
normal BMI. More clinical studies are necessary to discover the effect of 
aspirin on BMI and specifically fat distribution in obese individuals.
5.2 ADMA/DDAH system
5.2.1 Nitric Oxide
Nitric oxide (NO) may play a key role in the control of metabolic and 
cardiovascular homeostasis. In recent years human and rodent adipose tissue 
has emerged as a potential site of NO production. NO is a messenger for a
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wide variety of physiological functions. NO derived nitrite and nitrate 
concentrations correlate with body fat composition in humans. NO is also 
involved in adipose tissue biology by influencing adipogenesis, insulin- 
stimulated glucose uptake and lipolysis. NO induces lipid accumulation and 
lipogenic enzymes in rat white preadipocytes (Gaudiot et al, 1998). In vivo, 
insulin-stimulated glucose uptake in rat white adipose tissue was dependent 
on intact NO synthesis (Roy et al, 1998). NO inhibited lipolysis in human and 
rat subcutaneous adipose tissue depots (Andersson et al, 1999;Jordan et al, 
2001; Klatt et al, 2000). Based on these findings, NO appears to be an 
important mediator of adipocyte physiology with lipogenic properties (Engeli et 
al, 2004).
As the principal endogenous inhibitor of NO synthase, ADMA regulates rates 
of NO formation.
5.2.2 ADMA
ADMA is a novel risk factor for cardiovascular disease, which inhibits NO 
synthesis and causes endothelial dysfunction. ADMA, by blocking NO 
generation, initiates or encourages atherogenesis, plaque progression and 
plaque rupture. A causal relationship between increased ADMA levels and 
endothelial vasodilator dysfunction has been shown in many of conditions 
related to cardiovascular disease. ADMA is primarily cleared by catabolism 
through the activity of dimethylarginine dimethylaminohydrolase (DDAH). The 
ADMA/DDAH axis in adipose tissue was investigated to explain the 
association between insulin resistance and endothelial dysfunction in obesity 
(chapter 4).
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This study, for the first time, assessed the expression of DDAH and the 
production of ADMA from adipocytes and adipose tissue.
Both isoforms of DDAH were expressed in, and ADMA was released by, 
adipocytes. In organ cultures a correlation was observed between the adipose 
tissue mass and its release of ADMA and haploinsufficiency of DDAH 1 led to 
accumulation of ADMA. The release of ADMA from adipose tissue was 
confirmed in human subjects in vivo, and obese animals and humans have 
elevated circulating concentrations of ADMA and reduced adipose DDAH 
expression. Importantly, weight loss increased tissue DDAH expression and 
reduced ADMA. Treatment with an insulin sensitising agent, rosiglitazone, 
increased DDAH expression and decreased the output of ADMA from adipose 
tissue. The level of DDAH expression in adipose tissue is a key determinant 
of local ADMA levels and a target for novel therapies for obesity-associated 
pathologies.
Linking adipokines with ADMA/DDAH pathway will open another important 
regulatory pathway within the adipose tissue, as well as providing a causal 
link between insulin resistance and endothelial dysfunction in obesity. These 
results provide a novel, modifiable pathway in the tissue and a possible target 
for therapeutic intervention.
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Figure 5.2: Schematic pathway of DDAH/ADMA Pathway in adipose tissue
The ADMA/DDAH pathway is a novel, modifiable adipose tissue regulatory mechanism 
for nitric oxide bioavailability. Adipose tissue is a source of ADMA, an endogenous 
inhibitor of NOS. ADMA is mainly catabolised by DDAH. Treatment of adipose tissue 
explants with rosiglitazone (20pM) and TNFa (10pM) increased the expression of 
DDAH1. Furthermore ADMA release by the tissue was reduced in TZD and TNFa 
treated compared to untreated tissue. The effect of IL-6 and PGJ2 on adipose tissue 
DDAH expression and ADMA release was not significantly different from untreated 
tissue. Abbreviation: ADMA, Asymmetric Dimethyl Arginine; DDAH, Dimethylarginine 
dimethylaminohydrolase; IL-6, Interleukin 6; NO, nitric Oxide; NOS, nitric Oxide 
synthase; PGJ2, Prostaglandin J2; PRMT, Protein Arginine Methyl Transferase; TNFa, 
Tumor Necrosis Factor a; NC, no change.
□EiD: ;>  [
TNFa
iNOS
Figure 5.3: The effect of TNFa on NO production through DDAH and 
iNOS expression
TNFa induces DDAH-I protein expression in subcutaneous adipose tissue. 
Previous studies showed TNFa induces iNOS in endothelial cells. Induction of 
iNOS increases NO production; however increasing DDAH expression 
decreases ADMA levels. So it has been postulated that TNFa has the same 
effect on NO production in adipose tissue.
Abbreviation: ADMA, Asymmetric Dimethyl Arginine; DDAH, Dimethylarginine 
dimethylaminohydrolase; iNOS, Inducible nitric oxide synthase; NO, nitric 
Oxide; NOS, nitric Oxide synthase; TNFa, Tumor Necrosis Factor a.
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5.3 Future Work
This project introduces a new area of research with many questions remain 
unanswered and many interventions remain to be explored. Progress in 
molecular biology allows us to gain more insights into cardiovascular risk 
factors and also face a variety of interacting pathways and increasing number 
of different pathomechanisms reported for individual cases. Although a great 
work on secretory function of adipocyte and adipose tissue has been done, 
there is still much left to do. Listed below are several areas that look 
especially attractive for future exploration.
It could be investigated:
• Pharmacologic interventions in down stream part of COX pathway of 
IL-6 secretion by using selective EP2 and EP4 antagonist in vitro and 
in vivo.
• The effect of aspirin, selective COX-1 and COX-2 inhibitors on 
circulating IL-6 levels in lean and obese individuals.
• The effect of aspirin and selective COX-1 and COX-2 inhibitors on the 
level of adiponectin and other signaling molecules from adipose tissue 
in vivo and in vitro.
• The effect of aspirin and selective COX-1 and COX-2 inhibitors on 
adipogenesis specifically in individuals with BMI more than 30 and also 
its effect on fat distribution
• The effect of ADMA and SDMA on transcription factors and 
adipogenesis
• Interventional studies aimed at lowering ADMA production from 
adipocyte and adipose tissue.
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• The effect of dietary and pharmacological interventions with improved 
insulin sensitivity and endothelial dysfunction on adipose tissue 
expression of DDAH and release of ADMA
• Dietary and pharmacological interventions with their direct effect on 
adipose ADMA production and DDAH expression which could be a 
target for future therapies for obesity associated pathologies
• The effect of aspirin on ADMA production and also DDAH-1 and 
DDAH-2 expression in subcutaneous and epididymal adipose tissue 
with different time course and concentration
• The effect of leptin and other signalling molecules from adipose tissue 
on ADMA production and DDAH expression
These areas are a few of the many areas where further work might be 
focussed.
In the process of introducing the association between adipose tissue and the 
novel risk factors of coronary heart disease and type 2 diabetes it has been 
attempted to explore the molecular mechanism of the production of these 
molecules from adipose tissue and filling in as many details as was possible 
during a first exploration. It is our hope that other investigators will find some 
of these problems worthy of their attention.
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